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Despite cheap and effective vaccines, nearly 1.5 million children die each year from 
vaccine preventable diseases. The World Health Organization has called for novel vaccine 
technologies that can reduce needle-and-syringe use, reduce the dose of vaccine required, 
and reduce vaccine wastage, all while inducing an appropriate immune response. 
Microneedle patches offer a unique method of delivering vaccines into the skin without the 
use of needles and syringes. These patches consist of an array of needles in which each 
needle is composed of water-soluble polymers, sugars, excipients, and the vaccine. When 
inserted into the skin, the needles dissolve and deliver their embedded cargo. These patches 
meet a critical need for vaccination campaigns. They come in small, single dose packaging 
and can be administered by minimally trained personnel. Once dissolved, the needles leave 
no sharps waste. Additionally, the patches can be stored at elevated temperatures without 
damage to the vaccine. When the vaccine is delivered into the skin, studies have shown 
improved immune response compared to a standard intramuscular injection.  
This work developed two novel uses for microneedle patches. The first innovation 
delivers both measles and rubella vaccines in a single patch. Formulations were developed 
to minimize the loss of vaccine activity during the manufacturing process and subsequent 
storage at elevated temperatures. These patches were shown to be immunogenic in juvenile 
and infant rhesus macaques, and vaccination with a microneedle patch was able to protect 
the infants from a live measles viral challenge.  The second project investigated a novel 
vaccination strategy using daily dosing to improve the immune response compared to a 
bolus injection. In this work, daily intradermal injections or daily microneedle patches were 
 xvii 
used to deliver vaccines over the course of one month, and this regime induced responses 
comparable to two bolus doses. The microneedle technologies developed in this work can 






CHAPTER 1. INTRODUCTION 
1.1 Vaccination Campaigns  
Vaccines are acclaimed as one of the top ten public health interventions of the past 
century [1]. They have been influential in the eradication of smallpox, near eradication of 
polio, and significant reduction of disease [2]. However, over 19 million children do not 
receive the basic vaccinations recommended by the World Health Organization (WHO), 
resulting in approximately 1.5 million children deaths from vaccine preventable diseases 
each year [3]. While the number of vaccines administered has been rising, the Midterm 
Global Vaccine Action Plan in 2016 notes that vaccination coverage rates are stagnant and 
recommends the acceleration of novel vaccination technologies to improve global access 
to vaccination [2]. Currently, almost all recommended vaccinations occur using a needle 
and syringe to deliver the vaccine to the muscle or subcutaneous area. This technology has 
many setbacks, especially in developing countries with a common lack of infrastructure 
and resources.  New vaccination implementations should be small and easy to transport, 
thermostable, easy to administered, and immunogenic. Thus, there is a significant need for 
technologies that can easy logistics and reduce the costs of vaccinations.  
1.2 Microneedle Patches 
1.2.1 Dissolving Microneedle Patches   
Microneedle (MN) patches are a novel delivery technology to deliver drugs and 
vaccines into the skin and have been under development for the past twenty years [4]. 
These needles can be divided into four categories: (1) solid MNs which pierce the skin 
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followed by administration of the drug in liquid or patch form; (2) hollow MNs for delivery 
of a liquid drug solution; (3) metal MNs coated with a dried drug film; and (4) dissolving 
polymeric MN in which the drug is loaded in the polymer needle tip [5]. For the purpose 
of this work, only dissolving polymeric MN patches will be discussed further.  
MN patches consist of an array of polymeric MNs. Generally, this ~1 cm2 array 
consists of a 10x10 grid of needles, each several hundred microns tall, on a larger rigid 
backing [6-10]. The needles are composed of a variety of biocompatible, water-soluble 
materials such as sugars, carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), 
polyvinylpyrrolidone, and chitosan [4, 9, 11-14]. These materials encase the drug or 
vaccine in the tip of the MN. The MNs are mechanically strong enough to painlessly pierce 
the upper layers of the skin [6, 14-16]. The moisture in the skin dissolves the polymers and 
sugars and releases the cargo. After insertion, the backing material can be discarded as non-
sharp biomedical waste [16]. These patches have been used to deliver a variety of 
therapeutic molecules, such as DNA [17], insulin [8], small molecule therapeutics [18], 
and vaccines [9, 13, 16, 19, 20].  
1.2.2 Microneedle Patches for Vaccinations  
MN patches over numerous advantages over the traditional needle and syringe 
delivery technology in clinics in developed countries as well as rural vaccination 
campaigns. First, MN patches are packaged in small, single-use, single-dose units. This 
can increase the safety of vaccination while decreasing vaccine waste. For example, multi-
dose vials of vaccines are often used in vaccination campaigns leading to vaccine wastage 
if not all doses are used [21]. If only a few more patients are present at the end of a 
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vaccination session, health care workers must decide between (1) opening a new vial for a 
few children or (2) saving the vaccine but risking under vaccinating the community [21].  
Currently, vaccines are shipped through the cold chain in a lyophilized or liquid 
state. The cold chain is a sequence of refrigerators or freezers that maintain cold 
temperatures, typically 2-8˚C or -20˚C, respectively, from the manufacturing site, through 
regional distribution points, up to the vaccination site [22]. The cold chain is extremely 
expensive, costing $200-$300 million per year, and breaks in the chain can lead to vaccine 
wastage or administration of less-effective vaccines [23-26]. In the case of MN patches, 
the vaccine is entrapped in a dried state. Due to the immobility of the proteins, vaccine 
activity can be retained for longer time period at elevated temperatures [9, 26-29]. 
However, each vaccine requires a novel formulation which can retain vaccine activity 
during MN manufacturing and storage. These studies can be time and resource intensive 
[30].  
Prior to vaccination, lyophilized vaccines must be reconstituted with sterile liquid, 
mixed, and properly aliquoted. Reconstitution leads to potential mistakes, increases costs 
of vaccination campaigns, and requires staff training [31, 32]. Administration of MN 
patches is simple. No external paraphernalia such as reconstitution vials, sharps containers, 
needles, or syringes are required, thus reducing the weight that must be transported to and 
from vaccination sites [32]. Very little preparatory work is required for patch insertion. As 
compared to the Mantoux method which requires hours of training, MN patches can be 
administered via minimally trained personnel or even self-administered [16, 33]. This 
would be more cost-effective in vaccination campaigns or allow for in-home delivery of 
vaccinations [9, 34]. Once the patches are administered, the needles are fully dissolved and 
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can be discarded as biomedical waste, as a used bandage would be [5]. This eliminates the 
possibility of re-stick injuries or needle re-use.  Over one million deaths are caused each 
year due to re-stick injuries [35-37]; in 2017, 15 children died in Sudan due to needle re-
use during a measles vaccination campaign [38].  
Most vaccines require multiple doses to invoke a strong response in all patients 
[39]. MN patches can induce strong immune response to a vaccination and in some cases 
outperform other vaccination locations. MN patches deliver antigen into the skin, an organ 
rich in antigen-presenting cells such as epidermal Langerhans cells and dermal dendritic 
cells [40]. These cells are adept at encountering and responding to pathogens in the skin; 
effective lymphatic drainage can increase the immune system’s response. Due to the 
enhanced immune response, dose sparing (i.e. using a reduced dose to induce an equivalent 
response) has been demonstrated for some vaccines in animal models [41-44]. 
Additionally, MN patches have been shown to be more effective than IM injections in 
young mice [45]. Clinical trials have demonstrated that vaccination with MN patches can 
translate into humans [16].  
1.3 Measles and Rubella  
1.3.1 Disease Burden 
Measles virus remains one of the leading causes of vaccine-preventable deaths  
[46]. Measles infection is associated with a rash, fever, cough, and immune suppression 
[46, 47]. Respiratory tract infections and pneumonia are the most common measles-
associated deaths [46]. Measles is extremely infectious and spreads through aerosolized 
particles [47, 48]. Due to the high infectivity rate, high herd immunity over 95% is 
 5 
necessary to block disease transmission [46]. Before the introduction of the vaccine, over 
2 million deaths per year were attributed to measles [47]; in 2014, that number has fallen 
to 115,000 children each year [49]. In 2000, measles deaths accounted for 5% of all under-
five mortality [50]. Measles was eliminated from the US in 2000 [48]; however, it is 
making a comeback in small pockets of unvaccinated residents or in unvaccinated travelers 
[46, 48].  
Rubella is typically a much milder disease than measles. Older children and adults 
usually make a fully recovery after infection [49]. However, when pregnant women are 
infected, the infection can result in miscarriage or congenital rubella syndrome (CRS) [51]. 
CRS leads to disabling conditions affecting the heart, brain, eyes, and ears; over 100,000 
children are born each day with CRS [49]. A single case of CRS can cost over $75,000 
over a lifetime [52]. Rubella was eliminated from the Americas in 2015; however, global 
vaccination coverage remains low at 46% [49].  
1.3.2 Eradication Efforts  
In 2010, the WHO determined that measles can and should be eradicated [53]. In 
the following years, both the Measles and Rubella (MR) Initiative, supported by American 
Red Cross, CDC, the United Nations Foundation, UNICEF and WHO, and the Global 
Vaccine Action Plan have set out elimination goals. The initial goals were to eliminate 
measles in 5 WHO regions by 2020 [53]. The general strategy was to provide the first dose 
of measles vaccine via routine health services and the second dose of measles vaccine 
through mass vaccination campaigns. Through increased vaccination efforts, coverage rose 
to approximately 85% for the first dose of measles vaccine, 61% for the second dose, and 
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46% for the first dose of rubella vaccine [49]. From 2012-2014, 4.25 million measles deaths 
were averted [49]. However, vaccinations rates have stagnated, and an estimated 21 million 
infants did not receive their first dose of measles vaccines in 2008 [53]. This progress is 
insufficient to reach the 2020 elimination goals. Implementing novel vaccine technologies, 
building on the polio eradication efforts, and strengthening surveillance systems will be 
crucial in attaining the next phase of vaccination and elimination goals [53].  
1.3.3 Vaccines  
MR vaccines are extremely effective vaccines and have an estimated annual net 
benefit of over $9.7 billion dollars each year [54]. A dose between 103 and 104 tissue culture 
infectivity units (TCID50) of each of the live-attenuated vaccines is administered 
subcutaneously in 0.5 mL using a needle and syringe [55]. Measles, mumps, and rubella 
(MMR) vaccines were combined in 1971 [47]. The most common strains are Edmonstron-
Zagreb measles virus and Wistar RA 27/3 rubella virus [46, 55]. The lyophilized vaccines 
can be stored for at least two years at 2-8˚C, eight months at 22˚C, and one month at 37˚C 
[55]. Reconstituted vaccine is far less stable with 50% loss in one hour at 25˚C and almost 
100% loss in one hour at 37˚C. Additionally, the vaccine is sensitive to sunlight [55]. The 
vaccination invokes both humoral and cellular immune responses. IgM is present between 
two and six weeks after vaccination in serum, while IgG persists for many years [56]. IgA 
is found mostly in nasal secretions [56]. After a single dose, 95% of 12 month old children 
are protected from measles; vaccination at this age provides many years of protection, 
potentially lifelong protection [46, 47]. Vaccination can be boosted by vaccination or wild-
type exposure, with 99% of children seropositive after a second dose [46].  
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1.3.4 Alternative Delivery Methods  
To overcome the limitations of the current lyophilized, injected vaccines, other 
delivery methods have been developed and tested in animal models or the clinic with mixed 
success. Skin vaccination is a popular method for many of the reasons presented above. 
Transcutaneous immunizations were performed by tape stripping to remove the stratum 
corneum followed by liquid vaccine underneath a bandage. While being more acceptable 
by patients, the immune response was inferior to subcutaneous injection, probably due to 
incomplete delivery [57]. Jet injectors which use high-pressured stream of liquid to push 
through the upper layers of the skin have been used with more success. In clinical studies 
with MMR, this delivery method was well tolerated by patients and had minimal adverse 
events (i.e. site soreness, malaise, fever). In an adolescent (10-14 years) study, the jet 
injector performed equivalently to a needle and syringe [58]. Non-inferiority to needle and 
syringe delivery was demonstrated in toddlers (9-23 month); jet injector and needle and 
syringe outperformed bifurcated needle and nose drops delivering the same vaccine [59]. 
However, in infants, the response to rubella was non-inferior to needle and syringe delivery 
[60]. The measles and mumps seroconversion rates were inferior to the needle and syringe 
delivery. Study nurses noted skin wetness after some vaccinations using the jet injector, 
which could indicate that incomplete delivery is the cause of the lowered immune response 
[60].  
Aerosol vaccination can ease logistics of needle and syringe deliver and may better 
protect against measles viruses by vaccinating at the site of infection. In non-human 
primates, carbon dioxide assisted nebulization with a bubble-dryer (CAN-BD) vaccination 
offered complete protection from measles virus challenge [61]. However, intra-tracheal 
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delivery of dry powders produced an inferior response compared to an injection or 
nebulized aerosol [62, 63]. Clinical trials have produced conflicting results. First, in a study 
in children ages 5-14, aerosolized vaccines induced no serious side effects and had a similar 
immune response to subcutaneous injection [64]. In two adult studies, no safety issues were 
noted. The aerosol vaccination induced an immune response comparable to subcutaneous 
injection, but the differences between the two routes is hard to parse because all subjects 
were measles positive at time of vaccination [65, 66]. Finally, the only study delivering the 
first dose of measles vaccine with infant patients demonstrated that aerosolized vaccination 
was inferior to subcutaneous injection [67].  
1.3.5 Vaccine Stability  
Live-attenuated vaccines must retain their ability to infect host cells and replicate 
in order to induce a potent immune response. Inactivated measles vaccine was licensed in 
the early 1960s; however, this was discontinued after cases of atypical measles appeared. 
When vaccinated children became infected with measles virus, they experienced high 
prolonged fever, pulmonary nodules, extensive rash, and enlarged lymph nodes, indicating 
the need to deliver live viral particles not inactivated ones [68]. In order to meet the 
demands of vaccination campaigns, the WHO requires that novel MR vaccine technologies 
cannot lose more than one log of activity after one week at 37˚C [69].  The activity of these 
vaccines is measured via cellular assays, as previously described [70, 71].  
1.3.5.1 Dried state 
MR vaccines must maintain activity during MN patch manufacturing in which the 
vaccine is dried while under vacuum and during storage in which the patches are shipped 
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and may experience elevated temperatures. Lyophilized vaccines are more stable than in 
liquid state due to the immobilization of the proteins [72]. Two other methods have been 
developed to stabilize measles vaccine. First, CAN-BD creates powders of vaccine and 
excipients [73]. This method can lower the water content to 0.5%, compared with 1% in 
the lyophilized vaccine containing sorbitol. Low water content is important to maintain 
vaccine activity and retain powder integrity [73]. Trehalose and sorbitol maintained 60% 
of the original activity during drying, but myo-inositol was necessary to reduce loss during 
storage.  
Spray drying is gaining popularity due to its high-throughput, flexible 
manufacturing process. When spray drying measles vaccine, a mixture of excipients of 
sucrose, trehalose, arginine, human serum albumin, and glycerol in potassium phosphate 
buffer was necessary to maintain activity [74]. Divalent cations aided the long-term 
stability of the resulting powders. These powders lost one log of activity after 8 weeks at 
37˚C; during storage, the activity loss was biphasic - an initial rapid loss during the first 
week, followed by a considerably slower decline after that. This may be due to residual 
water loss during the initial week at elevated temperatures. 
1.3.5.2 Liquid state  
Understanding MR vaccine activity in the liquid state may not apply to the dried 
MN patch, but maintaining activity as a liquid may enable a more efficient patch 
manufacturing process. Rather than using the traditional cellular TCID50 assays, liquid 
formulations were screened by their prevention of aggregation measured by dynamic light 
scattering or by use of a measles virus which produces green fluorescent protein (MV-
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GFP). In general, proteins (i.e. gelatin), sugars (i.e. trehalose, lactose, dextrose), 
polyalcohols (i.e. mannitol, sorbitol), and amino acids (i.e. lysine, valine) with neutral 
buffers were able to stabilize liquid measles vaccine at elevated temperatures [75, 76].  
In order to fabricate patches, vaccines with high titers are necessary to load a full 
human dose in the needles. For this, preparations of highly purified, infectious viruses must 
be performed using gentle conditions. Tangential flow filtrations and diafiltration can be 
used to isolate vaccines; however ultracentrifugation has resulted in high loses of viral 
activity [71, 77]. The pH needs to be maintained between 5 and 9 to retain activity [77]. 
1.3.6 Maternal Antibodies  
Maternal antibodies inhibit early MR vaccination and lead to a window of 
susceptibility. Infants are vulnerable to many infectious diseases while their immune 
system develops. To protect them early in life, maternal antibodies are passed to offspring 
[78]. These antibodies are present for approximately 6-9 months after birth. Between the 
waning antibody levels and vaccination, the infants are susceptible to disease; 
approximately one third of global measles cases occur before 9 months of age [79]. In 
developed countries with herd immunity, children receive their first dose of MMR at 12-
15 months, which results in a 95% seroconversion rate [80]. Infants in developing countries 
vaccinated at 6-9 months have a much lower 60% seroconversion rate [80].Vaccination at 
6 month produces low humoral immunity, but comparable t-cell interferon ɣ response [81, 
82]. 
1.3.6.1 Infant Rhesus Macaque Model 
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Rhesus macaques have been used as a model for measles vaccination and infection 
because they share similar clinical reactions as humans [83]. In order to mimic maternal 
antibodies, an infusion of measles immunoglobulin can be infused prior to vaccination to 
induce similar humoral response as humans [84]. Newborn macaques receiving measles 
immunoglobulin had suppressed humoral and cellular immunity after vaccination [82]. 
DNA vaccination administered with IL2 adjuvant induced a potent, protective immune 
response [85, 86]. However, without the IL2, the DNA vaccine had a poor response 
compared to the live-attenuated vaccine in naïve infant rhesus macaques [87].  
1.3.7 Microneedle Patch  
Previous work in the Prausnitz lab and CDC has developed a measles vaccine 
microneedle patch. This patch was formulated with sucrose and threonine to maintain 
activity. The patch could be stored for four months with no loss at 5˚ or 22˚C and one log 
loss at 40˚C [88]. This patch induced potent immune responses in both cotton rats and 
rhesus macaques that were equivalent to subcutaneous injection [20, 88]. Finally, the 
patches were safe; no adverse events were noted in either animal model.  
1.4 Extended Delivery  
1.4.1 Benefits of Extended Presentation of Antigens  
Vaccines which mimic natural infection kinetics, such as MR, can induce life-long 
protection from a single dose. However, newer vaccines, typically killed vaccines, often 
have better safety profiles but are often less effective [89-92]. These vaccines typically 
require multiple doses in order to achieve high seroconversion rates. Adjuvants such as 
 12 
alum can improve the immune response [93]; however, few adjuvants are approved for use 
in vaccines [94]. Repeat vaccinations especially in developing countries are difficult to 
achieve and often leave coverage gaps. Because multiple doses must be spread months 
apart, 10 million children are under-vaccinated [39]. Thus, a single-dose vaccine could 
decrease the vaccination costs and increase vaccination coverage by eliminating booster 
shots [93].  
The concept that a controlled release of a vaccine may induce a stronger immune 
response compared to a bolus injection has been around since 1979 [93, 95]. Most of the 
work with antigen controlled release systems centers on poly(lactide-co-glycolide) 
(PLGA) microparticles. PLGA particles have been used to deliver tetanus vaccine [96-98] 
and hepatitis B vaccine [99-102] and have, in general, been shown to be superior to bolus 
delivery of antigen or alum-adsorbed antigen [39]. The size of the microparticle and the 
site of administration influence the immune response [93]. Two issues have hindered the 
translation of this technology: (1) the instability of the encapsulated antigen [103, 104] and 
(2) the profitability of such vaccines [93]. Other methods for controlled release including 
gelatin microspheres [93], hydrogels [105], chitosan microparticles [106], and chitosan 
gels [107] have successfully improved the immune response. Additionally, implants and 
osmotic pumps provide more control over the release profile of the vaccine compared to 
injected particles [104, 108, 109]. Most of the systems described above utilize similar 
release profiles with an initial burst followed by low levels of release; these studies 
demonstrate that longer presentation can increase the immune response, yet they cannot 
determine the optimal kinetics or fully elucidate why controlled release works better [89]. 
Controlled release of cancer antigens resulted in the accumulation of CD8+ T cells at the 
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site of vaccination rather than at the tumor site, limiting the vaccine effectiveness; more 
short lived formulations induced a more favorable outcome [110]. All work presented here 
will center on vaccines for prophylactic prevention of infectious diseases. 
1.4.2 Identification of Optimal Release Profile  
While many studies have demonstrated the benefits of continuous release of an 
antigen, few have studied the antigen kinetics that induce the most robust immune response 
[39]. Some studies have attempted to identify the optimal release profile by utilizing 
different types of controlled release systems. Different conclusions were reached; however, 
because different systems of various sizes (i.e. PLGA microparticle vs liposomes) were 
used, it is hard to determine if changes in immune response were due to the material or the 
kinetics [111, 112]. Another approach is to use daily injections that mimic different release 
profiles [92].  Using this method, confounding factors such as material, antigen stability, 
and host-material interaction are removed.  
Johansen et al. delivered a fixed dose of antigenic peptides and CpG as an adjuvant 
[92]. An exponentially increasing profile induced the highest CD8+ T cell responses 
compared to constant stimulation or bolus vaccinations. The number and activation levels 
of the dendritic cells were equivalent across groups, but the exponential immunization 
prolonged T cell proliferation and delayed dendritic cell recruitment [92]. Delivering 
human immunodeficiency virus antigens via subcutaneous injection or osmotic pump, Tam 
et al. demonstrated that exponentially increasing doses over two weeks induced highest 
antibody titers [109]. Using in vivo models and computation models, the authors concluded 
that the extended antigen presentation resulted in antigen retention in the draining lymph 
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nodes lead to an increase in B-cell differentiation in the lymph nodes and higher-affinity 
antibodies. In smaller studies, hollow MNs were used to deliver inactivated polio vaccine 
(IPV) into the skin with a constant or exponentially increasing profile for 4 or 8 days. 
Equivalent increases in IPV-specific IgG were seen across all extended delivery groups, 
but no differences between the different profiles were evident [113]. Finally, Jansen et al. 
was the only study that did not demonstrate an increase in immune response with daily 
injections compared to a bolus vaccination. This maybe be due to administering the vaccine 
in alternate sides of the chicken each day [114]. 
1.4.3 Slow Release from Microneedle Patches  
MN patches have been used to deliver controlled release vaccinations into the skin. 
PLGA with vaccine cast into the MN tips or loaded as particles can be rapidly delivered 
into the skin [115, 116]. When such patches were tested in vivo, they improved the cellular 
response and induced comparable serum antibodies to bolus vaccination [115]. Chitosan 
MNs on a non-dissolving pedestal delivering ovalbumin over at least two weeks showed 
increased antibodies post vaccination [14]. MN patches containing poly(acrylic acid) and 
silk released ovalbumin for over two weeks. The release profile was an initial boost 
followed by low release over two weeks. In vivo, these MN patches increased proliferation 
of antigen-specific CD8+ T cells, prolonged local inflammation, and heightened the 
humoral response [117]. Furthermore, repeated application of dissolving MN patches in 
mice did not prompt any undesirable side-effects in the skin [118]. This may be a method 
for multiple deliveries of vaccines. 
1.4.4 Vaccines Utilized  
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This work studies three other vaccines besides MR which was previously 
discussed: IPV, tetanus toxoid, and influenza. In all of these cases, the vaccine is an 
inactivated viral particle or protein; these vaccines do not induce potent, long lasting 
immune responses after a single dose. The eradication of polio is quickly approaching, with 
only 342 cases worldwide in 2014 [119]. To attain eradication, IPV must be incorporated 
in global vaccination campaigns. IPV is a formalin-inactivated vaccine that has three 
serotypes, each of which must be vaccinated against [120]. IPV requires at least three doses 
to meet high seroconversion levels [119].  Each dose costs at least about three dollars and 
is administered with a needle and syringe [120].  
Clostridium tetani spores in the soil and environment can enter the body through 
cuts or abrasions on the skin where the bacteria can replicate and release toxoid, resulting 
in damaging neurological effects [121]. The WHO recommends six doses of tetanus toxoid 
vaccine spread from infancy to adolescence, followed by an additional boost every ten 
years [122].  
Finally, subunit influenza vaccine is administered each year to prevent seasonal flu. 
In the 2015-2016 influenza season, the vaccination prevented approximately 5 million 
illnesses, 2.5 million medical visits. Due to antigenic changes, each year, three different 
strains are selected to be in the vaccine, and the population must be re-vaccinated [123]. 
The vaccine efficacy for influenza varies year-to-year but hovers around 50-60% [123]. 
For each of these vaccines, novel vaccine technologies that improve the immune response 
to a single dose could improve coverage and disease protection. 
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CHAPTER 2. OVERVIEW OF AIMS 
2.1 Aim 1: Thermostability of Measles-Rubella Vaccine in a Microneedle Patch 
In this aim, we hypothesize that the optimization of excipients using a screening 
process will result in a formulation that stabilizes live-attenuated measles and rubella 
vaccines during the microneedle patch manufacturing and storage. Vaccine stability when 
stored at elevated temperatures is crucial to the introduction of patches for developing 
countries. The removal of the cold chain will enable simpler house-to-house vaccination 
campaigns, reduce vaccine waste, and decrease the costs associated with vaccine 
administration. To achieve this goal, the effects of buffer and pH on vaccine activity during 
drying were studied. While measles vaccine is not susceptible to pH from 6.0 to 8.0 during 
drying, drying rubella vaccine at pH lower than 6.5 had a significant loss of activity; drying 
at pH 7.5 was optimal for maintaining stability. We then screened buffers with the capacity 
to buffer at pH 7.5; an overnight drying experiment showed potassium phosphate buffer to 
be suitable to both vaccines. Excipients such as sugars, amino acids, and proteins were 
chosen from the literature and previous lab experience. Two consecutive experiments 
tested the excipients stabilize potential during an overnight drying step and then during 
accelerated storage at 40˚C for one week.  A smaller subgroup of excipients was tested in 
pairwise manner for stability for up to one week at 40˚C. Sucrose-threonine was identified 
as the top combination. Finally, vaccine microneedle patches fabricated with sucrose-
threonine maintained vaccine activity for at least one month at elevated temperatures and 
were able to withstand freeze thaw cycles. The thermostable MN patches developed in this 
work will decrease vaccine waste, allowing for cheaper, easier vaccinations.  
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2.2 Aim 2: A Microneedle Patch for Measles and Rubella Vaccination is 
Immunogenic and Protective in Rhesus Macaques 
The second aim centers on the immune response to microneedle patch delivery of 
live attenuated measles and rubella vaccine in rhesus macaques. The central hypothesis is 
that microneedle patches would induce a comparable immune response compared to 
subcutaneous injections which are the traditional route of vaccination. In the first study, 
juvenile rhesus macaques vaccinated with microneedle patches or subcutaneous injection 
showed comparable neutralizing antibody and IgG titers against both vaccines. The 
secondary purpose of this aim is to study the immune response in the presence of maternal 
antibodies. For this, infant macaques born to measles-naive mothers were vaccinated with 
or without an infusion of measles IgG. Animals vaccinated without maternal antibodies 
developed strong immune responses that later protected against a live measles viral 
challenge. Those vaccinated in the presence of maternal antibodies produced inferior 
responses and displayed signs of infection after viral challenge. Thus, microneedle patches 
induce a potent immune response that is non-inferior to subcutaneous vaccination.  
2.3 Aim 3: Extended Delivery of Vaccines to the Skin Improves Immune Response  
In the final aim, we examine the effect of vaccine extended delivery and 
presentation on the immune response. We hypothesize that vaccine release profiles that 
mimic natural infection kinetics will induce potent immune responses and that these 
profiles can be presented utilizing daily injections or microneedle patches. Through studies 
using inactivated polio vaccine and daily intradermal injections, we identified that a 
constant profile over one month induced the highest neutralizing antibody titers of the 
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profiles we tested. This principle applies to other inactivated or dead vaccines such as 
tetanus toxoid vaccine or subunit influenza vaccine; however, no improvement was seen 
when vaccination with live-attenuated measles vaccine. Finally, microneedle patches 
containing influenza vaccine were administered to mice over the course of a month; the 
animals displayed high hemagglutinin-inhibition titers compared to bolus vaccination or 
intradermal extended delivery injections. Extended delivery with microneedle patches 
elicited heightened humoral and cellular responses compared to bolus vaccination. 
Together, this aim develops a novel technique of utilizing extended delivery to improve 




CHAPTER 3. THERMOSTABILITY OF MEASLES-RUBELLA 
VACCINE IN A MICRONEEDLE PATCH 
Measles and rubella vaccinations are highly effective at reducing disease 
prevalence; however, high costs related to administration and vaccine waste limit the extent 
of vaccine coverage. Microneedle (MN) patches can increase coverage by easing logistics 
and reducing costs. Here, we demonstrate the thermostability of a bivalent measles and 
rubella vaccine MN patch. We identified the need for a buffer during drying for rubella 
vaccine; potassium phosphate buffer at neutral pH was optimal for both vaccines. After 
screening 43 excipients for their ability to retain activity during drying and storage, a 
smaller subset of excipients was selected, and excipients were dried in pairwise fashion. 
Dried vaccine was stored for one week at 40°C; numerous combinations were able to 
maintain activity of both vaccines over this time. MN patches were fabricated with a 
sucrose-threonine-potassium phosphate buffer formulation and stored at various 
temperatures. These patches had no significant loss of activity after one month at 40˚C and 
had not passed the one log cut off after four months at lower temperatures. This work 
demonstrates the potential for MN patches to be removed from the cold chain, thereby 
decreasing vaccine cost and waste and increasing vaccination coverage.  
3.1 Introduction  
Elimination efforts rely on vaccines to protect the population, and vaccination 
coverage levels of over 95% are necessary in order to impede viral transmission [124]. 
However, vaccination rates for measles and rubella have stagnated over the past several 
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years [2, 50], contributing to 114,000 measles deaths in 2014 [49, 50] and over 100,000 
children born with congenital rubella syndrome (CRS) [51]. In 2012, the Measles and 
Rubella Initiative, a group of UNICEF, World Health Organization (WHO), Centers for 
Disease Control and Prevention (CDC), the United Nations Foundation, and the American 
Red Cross set regional elimination goals for 2015 [49, 53]. These goals were not achieved 
in part due to limitations of current vaccination technologies to reach all populations 
needing vaccination [49].  
The measles and rubella (MR) vaccine is stored in lyophilized ten-dose vials and 
administered using a needle-and-syringe. This method is expensive and resource heavy, 
which limits access to vaccination to populations in developing-country or hard-to-reach 
communities [125]. The lyophilized vials must be reconstituted properly before 
administration, requiring a trained health care professional. The needle and syringe used to 
administer the vaccine must be properly discarded after use to prevent injury to the patient 
or health care worker. In a recent vaccination campaign, 15 children died due to improper 
vaccine handling and needle re-use by untrained personnel  [38].  The vials must be thrown 
out six hours after reconstitution, leading to notable levels of waste [32]. Finally, the need 
to maintain the cold chain is expensive and leads to vaccine wastage. The current 
lyophilized vaccine is stable at 4˚C for up to two years but only four weeks at 37˚C [126]. 
Breaks in the cold chain may lead to vaccine failures and potentially disease outbreaks 
[127, 128]. Due to gaps in the cold chain, approximately half of the vaccine vials had below 
the minimum potency dose when delivered to Brazil [129] or Nigeria [130]. One review 
estimated that 75-100% of shipments are exposed to freezing temperatures [131]. Once 
reconstituted, within one hour, approximately half of the activity is loss if the vaccine is 
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stored at 20˚C, while almost all of the activity is lost if kept at 37˚C [32, 126]. Therefore, 
vials must be discarded after 6 hours due to this loss of potency.  The wastage factor or the 
number of vaccine doses wasted per dose administered is estimated at 3.4 for routine 
vaccination and 1.1 for supplemental immunization activities (SIAs) [132]. WHO requires 
novel MR vaccines technologies to withstand storage for one week at 37˚C without loss of 
more than one log10 of activity [49, 74, 133]. Due to the complexity of administration, 
house-to-house vaccination campaigns are limited, despite their ability to increase 
vaccination coverage [134]. Therefore, in order to reach the next set of regional and global 
elimination goals, there is a need for a novel vaccination technology that is single dose, 
eliminates needles, easily administered, and thermostable [32].  
Microneedle (MN) patches provide a novel vaccine delivery method with the 
potential to increase vaccination coverage. MN patches consist of an array of water-
soluble, solid, conically shaped needles attached to a patch backing [8, 10, 12, 115]. Each 
microneedle contains the vaccine entrapped in polymers, sugars, and other excipients 
[135]. Once these sharp needles painlessly pierce the skin, they fully dissolve, deliver the 
vaccine, and result in no sharps waste [4, 5, 26, 136, 137]. MN patches are available in 
single dose-single use packaging, reducing vaccine waste and easing administration [32]. 
Once dissolved, the microneedles cannot be re-used, which increases the safety of the 
vaccinator and the patient and reduces the waste that must be moved from the vaccination 
site. Additionally, these patches can be administered by minimally trained personnel, again 
reducing costs associated with each vaccination [20, 32, 33]. Finally, because the vaccine 
is stored in the dried state, vaccines generally show superior thermostability compared with 
liquid or lyophilized vaccines [9, 28, 29, 88, 138]. However, each vaccine that is 
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incorporated into a MN patch requires its own formulation to stabilize the vaccine during 
patch manufacturing and storage [29, 30].  
The current MR vaccine is packaged in lyophilized vials. These vials must be 
shipped between 2 and 8˚C. Other methods of measles vaccination have employed carbon 
dioxide-assisted nebulization with bubble dryer (CAN-BD) or spray drying to stabilize 
measles vaccine. CAN-BD creates a dry powder with about half the water content of 
lyophilized vaccines that can be delivered via aerosol into the lungs. Measles vaccine 
powder with myo-inositol and sugars saw a 0.6 log10 loss during storage for one week at 
37˚C [73, 139]. Spray drying can increase manufacturing throughput compared to 
lyophilized vials but must be reconstituted before administration. A combination of 
sucrose, trehalose, arginine, human serum albumin, and divalent cations stabilized measles 
vaccine for 8 weeks at 37˚C for one log10 loss with no loss observed over that time at 4˚C 
[74]. To our knowledge, no study has been performed on the stability of both vaccines 
together. 
In previous work, MN patches were developed to deliver measles vaccine. These 
patches were thermostable with one log10 loss of activity after four months at 40˚C and 
were immunogenic in cotton rats and rhesus macaques [20, 88]. As global measles 
eradication efforts ramp up, there is a focus to include rubella vaccinations as part of the 
measles vaccination campaigns [125]. To that end, novel formulations should be developed 
to incorporate both measles and rubella vaccines into a single MN patch. Here, a 
methodical screen was used to identify a formulation that maintains stability of a bivalent 
MR patch during manufacturing and at elevated temperatures for at least one month. We 
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also demonstrated that these patches exceed the WHO requirements for novel MN vaccine 
technologies.  
3.2 Materials and methods  
3.2.1 Vaccines 
MR vaccines were prepared as described previously [20]. Briefly, stocks of 
monovalent measles or rubella vaccines (generously provided by Serum Institute of India, 
Pune, India) were added to confluent flasks of Vero cells (ATCC Manassas, VA) with 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Grand Island, NY) and 2% fetal 
bovine serum (FBS, Gibco) and incubated for five days at 37°C. Cellular suspensions were 
freeze-thawed and centrifuged to remove the cellular debris. Measles vaccine titers were 
approximately 7 log10 TCID50/ml, and rubella vaccine titers were approximately 5 log10 
TCID50/ml. Vaccine aliquots were stored at -80˚C until use.  
3.2.2 Sample preparation and storage  
Measles and rubella vaccines were formulated into casting solutions to be used in 
the MN patch fabrication. All excipients were purchased from Sigma Aldrich (St. Louis, 
MO). Measles vaccine was used as prepared at a titer of 7 log10 TCID50/ml. Rubella vaccine 
was concentrated using Vivaspin filters (Sartorius, Goettingen, Germany) with a 300 kDa 
molecular weight cut off until the volume decreased ten-fold. Measles or rubella vaccine 
was mixed with excipient solutions to achieve final casting solution concentrations of 10% 
w/v excipient and 1% w/v carboxyl-methylcellulose (CMC) in buffer. If the solubility of 
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the excipient was lower than 10%, the maximum solubility was used instead. For pH and 
buffer screens, casting solutions containing 10% sucrose and 1% CMC were used.  
As an initial screening process, 50 µl casting solutions of different formulations 
were cast into Eppendorf microcentrifuge tubes. These samples were dried overnight under 
vacuum with desiccant at room temperature (20-25°C). The following day, samples were 
packaged in sealed aluminum pouches (Oliver-Tolas Healthcare, Grand Rapids, MI) with 
desiccant and placed in stability chambers (Caron, Marietta, OH) at 5, 25, or 40°C.  
3.2.3 Microneedle patch preparation 
MN patches were prepared as previously described [9, 88]. First, MN patch molds 
were prepared, as previously described [140]. Then a casting solution was cast onto PDMS 
molds. The solution was dried into the tips of the cavities under vacuum, and excess 
solution was removed. A second cast of 28% w/v poly-vinyl alcohol (PVA, Acros 
Organics, Geel, Belgium) and 21% w/v sucrose was added to the molds. Following two 
days of drying at room temperature with desiccant, patches were demolded and packaged 
with desiccant as described above for storage in stability chambers at 5, 25, or 40°C.  
3.2.4  Measles infectivity assay 
Samples were reconstituted in 1 mL DMEM. Tenfold dilutions of the sample were 
added to Vero cells seeded on 48 well plates with DMEM with 2% FBS. After five to seven 
days of incubation, plates were incubated with crystal violet, and titers were counted using 
the Spearman and Karber algorithm [141].  
3.2.5  Rubella infectivity assay 
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To determine the rubella vaccine titer, samples were reconstituted in 1mL DMEM 
[70]. If the sample contained measles vaccine, anti-measles IgG (EMD, Millipore, 
Billerica, MA) was incubated at a 1:500 dilution with the sample for 1 hour at 37˚ C. Then, 
tenfold dilutions of the sample were incubated on Vero cells and incubated for one hour at 
37˚ C followed by the addition of a mixture of DMEM, avicel (FMC BioPolymer, Newark, 
DE), and FBS. After three to five days, cells were fixed in cold methanol, incubated with 
E1 antibody (CDC, in-house), HRP-conjugated antibody, and precipitating TMB (Clinical 
Science Products, Mansfield, MA). An ELISPOT analyzer (CTL, Cleveland, OH) was used 
to count the foci.  
3.3  Results  
3.3.1 pH and buffers  
We first wanted to determine the effect of pH on measles and rubella vaccine 
stability during drying. Potassium phosphate buffer was selected due to its ability to buffer 
across the selected pH range of 6.0 – 8.0. After drying, there was no significant loss of 
measles vaccine activity after drying over the pH range studied (Figure 3.1, top, ANOVA, 
p=0.764). On the other hand, rubella vaccine activity was significantly lower after drying 
at low pH or in unbuffered water (ANOVA, p<0.0001). Drying at pH 7.0 to 7.5 was 
significantly improved compared to drying in water but not statistically different from one 
another (p=0.999 and 0.447 for measles and rubella, respectively). Drying at either pH 
resulted in no loss of activity for rubella vaccine but some loss for measles vaccine (dotted 
line).  
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Although potassium phosphate buffer was effective, we next wanted to optimize 
the choice of buffers. Six buffers with buffering capacity around pH 7.0 and 7.5 were 
selected and screened for activity after drying. For measles vaccine, M199 and histidine 
buffers had lower activity compared to the other four buffers (Figure 3.1, bottom, ANOVA, 
p=0.031). For rubella vaccine, M199 and ammonium acetate buffers had lower activity 
upon drying; an ANOVA analysis comparing DMEM, HEPES, and potassium phosphate 
showed that they were not significantly different in their ability to stability measles or 
rubella vaccines (p=0.408). Based on these data combined, potassium phosphate was 
selected as the buffer to use in subsequent experiments because it showed good results with 
both vaccines and is the buffer currently used in commercial MMR vaccines [142].  
  
Figure 3.1. pH and buffer.  
Samples show increased vaccine activity when dried at neutral pH. (TOP) 
Monovalent vaccine samples were dried in potassium phosphate buffer over a pH 
range or deionized water. Rubella vaccine loses activity when dried at low pHs. 
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(BOTTOM) When dried in a variety of buffers, DMEM, HEPES, and potassium 
phosphate all performed equivalently. Dotted lines indicate liquid controls (n=2 or 4).    
3.3.2 Single excipients during drying  
Forty-three excipients, such as sugars, amino acids, proteins, and salts, were 
selected from literature and ingredients lists of currently approved vaccines. Each excipient 
in potassium phosphate buffer was mixed with the vaccine, and solutions were dried 
overnight in Eppendorf microcentrifuge tubes under room temperature vacuum and in the 
presence of desiccant. The remaining activity of rubella vaccine after drying (Figure 3.2, 
grey bars) shows that many excipients were able to maintain measurable level of activity.  
However, measles vaccine was more susceptible to damage due to drying, and many fewer 
excipients were able to maintain measles vaccine activity after drying (black bars). 
Excipients that maintained activity above the detection limit for both vaccines were 




Figure 3.2. Screen excipients in overnight dry.  
Excipients were mixed with monovalent vaccine, dried overnight at room 
temperature, and reconstituted for analysis. The solid lines represent the lower 
detection limit for each assay (black for measles, grey for rubella). Excipients that did 
not retain any activity were eliminated for the next phase (n=2). 
3.3.3 Single excipients during storage  
We next studied the effect of excipients on thermostability of measles and rubella 
vaccines during storage at elevated temperatures. Single excipients were mixed with 
vaccine, dried overnight at room temperature, and then stored at 40˚C with desiccant. After 
seven days, only three excipients had detectable measles vaccine activity: histidine, 
sucrose, and trehalose. For rubella vaccine, roughly two thirds of the excipients had some 
activity by day 7. There are two sources of activity loss: drying and storage. Certain 
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excipients were effective at maintaining stability during drying. To separate the two effects, 
activity at day 0 was compared to the liquid control representing no loss of activity (dotted 
line, Figure 3.3 and Table 1). From this analysis, several excipients such as sorbitol, 
dextrose, and gluconate, were selected for the next round. Other excipients were more ideal 
for reducing activity loss during the storage at elevated temperatures. The viral activity 
after one week was compared to the activity after drying at day 0. From these percentages, 




Figure 3.3. Single excipients storage screen.  
After drying, samples were stored at 40°C for up to one week. The dotted lines 
represent 100%. During storage, only three excipients (histidine, sucrose, and 
trehalose) were able to maintain any measurable level of activity (TOP). For rubella, 
most of the excipients were able to maintain some activity (n=2). 
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3.3.4 Combination of excipients  
We hypothesized that by combining excipients, certain pairs of excipients would 
demonstrate better stability than either of the individual excipients alone. Stabilizers from 
the previous screen were selected for their ability to stabilize during drying and/or during 
storage. The stabilizers were combined in pairwise fashion and compared the titers at day 
0 and day 7 after storage at 40°C to two controls: sucrose-threonine, which was the 
excipient formulation used in a previous study of measles vaccine MN patch stabilization 
[88] and the liquid control (dashed line, Figure 3.4, Table 2, and Table 3). Three excipient 
combinations, histidine - sucrose, histidine - sodium gluconate, trehalose - asparagine, 
showed no statistical loss in activity between stock - day 0 and day 0 - day 7 (two t-tests, 
p>0.05).  We also compared the remaining activity at day 7 to the activity of sucrose -
threonine at day 7. Several combinations had higher activity for either measles or rubella 
vaccine, but no combinations had higher mean titers for both vaccines. In general, sugars, 
such as sucrose and trehalose, were good stabilizers for drying and storage of both 
vaccines. Histidine was a particularly good stabilizer during drying for measles vaccine. 
Taken together, using a screening process, we identified excipient formulations that can 
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Figure 3.4. Combinations of two excipients screen.  
Pairwise combinations of excipients were mixed with monovalent vaccine, dried 
overnight, and stored with desiccant at 40°C for one week. Titers after drying (Day 
0, black bars) and after storage (Day 7, grey bars) are represented for each vaccine. 
The dotted lines represent 100% activity for each vaccine. Combinations outperform 
their single excipient components (n=2).  
 33 
3.3.5 Storage in microneedle patches  
Until now, stability was studied by casting solutions into tubes. In the final study, 
we wanted to look at the stability of MR vaccines in MN patches over a range of 
temperatures. MN patches were fabricated with 10% sucrose, 3% threonine, and 1% CMC 
in potassium phosphate buffer. Patches were stored at 5, 25, or 40˚ C with desiccant. After 
one month, no statistical difference was noted at any temperature for any vaccine (Figure 
3.5, t-test, p>0.01). By the two-month time point, the rubella vaccine titer was statistically 
lower at all time points than day 0 (p=0.0078, 0.0029, and <0.0001 for 5°, 25°, and 40°C 
respectively), while measles vaccine remained stable for 4 months. For the first time, we 
have shown that a MR vaccine microneedle patch is stable at elevated temperatures for at 
least one month. This surpasses the WHO requirements for stability at 37˚ C for one week.  
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Figure 3.5. Microneedle patches were stable at elevated temperatures.  
Bivalent microneedle patches were fabricated with sucrose and threonine and stored 
at 3 temperatures. No loss of activity was seen over the first month of storage (n=4).  
3.3.6 Freeze thaw cycles  
During vaccine transportation in the cold chain, vaccines may experience 
fluctuating temperatures. If packaged adjacent to ice packs, vaccines may be exposed to 
near freezing conditions. To test vaccine stability in these cases, MN patches were exposed 
to freeze thaw cycles, where temperatures shifted from 5°C to -20°C every hour and a half. 
After one or three cycles, patches were stored overnight at 5°C. The resulting titers were 
normalized by the titer for patches stored at 5°C (Figure 3.6). While there was some loss 
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in the measles vaccine titer, no statistically significant differences were detected between 
the groups (ANOVA, p=0.25).  
 
Figure 3.6. Stability following freeze thaw cycles. 
MR MN patches were fabricated and packaged with desiccant. Vaccine titers were 
analysed after storage at 5°C, 25°C, one freeze thaw cycle, or three freeze thaw cycles. 
Titers were normalized by the activity of patches stored at 5°C. Although there was 
loss detected in the measles titers, here was no statistical difference across any of the 
groups (ANOVA, p=0.25, n=4).  
3.4 Discussion  
The licensed measles and rubella (MR) vaccine is safe and highly effective at 
prevention of disease. However, the current technology to deliver the vaccines faces 
numerous challenges, limiting the widespread use of the vaccine and hindering elimination 
efforts.  To our knowledge, this is the first time that the thermostability of both measles 
and rubella vaccines has been studied simultaneously for the development of MN patches. 
We demonstrate that through a screening process we identified a formulation that kept both 
vaccines stable for at least one month at elevated temperatures. This surpasses the WHO 
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requirement for novel MMR vaccine products to lose up to one log10 of activity after one 
week at 37˚ C.  
When we screened drying of the vaccines in buffers, the presence of a buffer is 
extremely important to maintain rubella vaccine activity during drying, unlike measles 
vaccine. The E1 and E2 proteins on the rubella virus membrane undergo a conformation 
shift between pH 5 and 6 [143, 144]. Once exposed to a low pH environment, the rubella 
virus shows a remarked reduction in infectivity [143]. Additionally, the pH of a solution 
drops as water is removed through crystallization during freezing or evaporation during 
drying [145]. The decrease in pH has been shown to influence protein conformations and 
result in denaturation [146, 147]. These literature observations are consistent with our 
finding that buffer at neutral pH is essential to maintain activity of rubella vaccine during 
drying.  
In the next part of the screen, we studied the effects of various excipients to stabilize 
MR during drying and storage. During drying and storage, one of the key stresses on the 
proteins is the removal of the protein’s hydration shell [148]. Sugars, such as sucrose, 
trehalose, and gluconate, could provide hydrogen bonding to the protein and serve as water 
substitutes during drying [148, 149]. Depending on their side chains, amino acids stabilize 
proteins in the dry state through a variety of mechanisms, including ionic interactions, 
reducing exposed hydrophobic regions, filling of void volumes, and slowing the molecular 
dynamics [150, 151]. We further demonstrated that solutions with two excipients 
outperformed the single excipients during drying and storage. This is consistent with other 
literature which show co-solutes are beneficial in protein stability [9, 88, 151, 152].  
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Microneedle patches offer many advantages over current needle and syringe 
delivery technology.  MR elimination and possible future eradication efforts rely on high 
vaccination coverage to meet their goals; however, these efforts are hindered by the 
reliance of current lyophilized vaccines. MN patches remove many barriers in vaccination 
campaigns such as biohazardous sharps waste, single-dose packaging, and administration 
by minimally trained personnel.  
Here, we demonstrate the development of a bivalent measles-rubella MN patch 
which can be stored at 40˚ C for up to one month with no loss of vaccine activity, with up 
to four months at 5°C with less than one log10 activity loss. These findings exceed WHO 
requirements for one log10 loss after one week at 37°C. While our findings may not allow 
for complete removal from the cold chain, it does suggest that patches could be transported 
in a controlled temperature chain, in which the ‘last mile’ may be conducted outside of the 
cold chain. During a vaccination campaign, patches could be refrigerated from 
manufacturer to central distribution points and district level sites. During the last phase in 
which vaccinators go house-to-house or which take place in remote areas, patches could 
be stored at ambient temperature without the need for any refrigeration. This contrasts with 
lyophilized vaccines. These vaccines must constantly be kept on ice even when accessing 
remote locations, as the ice is necessary to keep the reconstituted vaccine cold during the 
vaccinations. Thermostable MR MN patches may allow for a different vaccine vial monitor 
(VVM) to be used. Current lyophilized measles or MR vaccines are manufactured with a 
VVM14 for medium stability. This medium monitor allows for 14 days at 37°C, 90 days 
at 25°C, or 3 years at 5°C. If VVM30 were used, vaccine could be stored for longer times 
at mid to high temperatures, thereby reducing vaccine waste.  
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Increasing global vaccination coverage rates have drastically diminished the 
mortality and disease burden of MR. However, coverage rates have stagnated due, in part, 
to use of a needle and syringe with a lyophilized vaccine. This vaccine must be refrigerated 
during shipment, once reconstituted, can only be used for 6 hours. Here, we have 
demonstrated that measles-rubella vaccine microneedle patches can be stored at elevated 
temperatures without loss of activity. These patches may allow for partial removal from 
the cold chain. The added thermostability can decrease costs and logistics necessary for 
mass vaccination campaigns. Overall, if implemented in routine and supplemental 
immunization activities, MN patches can increase vaccine coverage and aid in elimination 
and eradication efforts.  
3.5 Conclusion  
In order to eliminate and eventually eradicate MR, higher vaccination coverage is 
necessary. The global health community has called for improved vaccine delivery devices 
that can ease administration, are thermostable, and do not require needles. To this end, we 
developed thermostable MR MN patches that can painlessly delivery vaccine into the skin. 
We studied the effects of pH and buffers on vaccine stability during drying, finding that 
potassium phosphate buffer at pH 7.5 to be optimal. Next, 43 excipients were narrowed 
down by their ability to maintain activity during drying and storage, and top excipients 
were tested as pairs. Sucrose-threonine- potassium phosphate MN patches were then tested 
for long term stability. After one month at 40°C, no statistically significant activity was 
noted, exceeding the WHO requirement for one log10 loss after one week. After two 
months, titers for rubella vaccine had fallen below that threshold. MN patches were not 
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susceptible to loss during freeze thaw cycles. In conclusion, the thermostable MR MN 




CHAPTER 4. A MICRONEEDLE PATCH FOR MEASLES AND 
RUBELLA VACCINATION IS IMMUNOGENIC AND 
PROTECTIVE IN RHESUS MACAQUES 
Despite the availability of safe, efficacious vaccines, measles and rubella (MR) 
remain major public health concerns especially in developing nations with low vaccination 
coverage rates. New vaccination delivery methods may help increase coverage to allow 
countries to achieve regional elimination goals and enhance control of MR and congenital 
rubella syndrome. Microneedle (MN) patches consist of micron-scale projections 
composed of water-soluble materials, encasing the vaccines. These patches can be 
administered by minimally trained personnel, leave no biohazardous sharps waste, and 
remove the need for vaccine reconstitution. The goal of this study was to evaluate the 
immunogenicity of MR vaccination using MN patches in juvenile rhesus macaques and in 
infant rhesus macaques in the presence or absence of measles maternal antibody (MiG). In 
juvenile rhesus macaques, MN patches induced comparable immune response to 
subcutaneous injection (SC). In the infants in the absence of MiG, protective titers of 
measles neutralizing antibodies (>120 mIU/ml) were detected in 100% of macaques in the 
MN group and in 50% of macaques in the SC group post-vaccination. However, protective 
titers to measles were not detected in either of the groups that received MiG prior to 
vaccination. Rubella neutralizing antibody titers were in excess of 10 IU/ml for all groups. 
All macaques in the MN group were protected from measles challenge, while 75% were 
protected in the SC group; none of the macaques that received MiG were protected. These 
results show, for the first time, that a single dose of MR vaccine delivered by MN patch 
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generated protective titers of neutralizing antibodies to both MR in rhesus macaques and 
afforded complete protection from wild-type measles virus challenge.   
4.1 Introduction  
Measles and rubella have been effectively controlled in many parts of the world by 
achieving high levels of coverage with measles and rubella vaccine. However, global 
vaccination coverage has plateaued at approximately 85%, and measles and rubella 
continue to circulate in countries with inadequate coverage. Measles caused 135,000 deaths 
in 2015, and 100,000 children are born with congenital rubella syndrome each year. The 
World Health Organization (WHO) established regional vaccination coverage goals of 
≥90% nationally and ≥80% in every district [47]. However, utilizing current vaccination 
methods, vaccination coverage has stagnated around 85% for the first dose of measles-
containing vaccine and 56% for the second [49]. While this increased vaccination rates 
account for a 79% decrease in measles-attributed deaths over the past fifteen years, this 
decrease was  insufficient to reach 2015 global goals [47]. Rubella had much lower global 
vaccination coverage of 46% in 2014 [49]. Congenital rubella syndrome (CRS) or the 
infection of a pregnant women and her child can result in miscarriage, fetal death, or 
disabling conditions such as heart disease, blindness, and deafness; increases in vaccination 
coverage have not alleviated the incidence of CRS over the past twenty years [51].    
Smallpox eradication in 1980 and on-going polio eradication efforts over the past 
twenty-five years have been successful largely due to administration of the vaccine in 
house-to-house campaigns by millions of minimally trained volunteers and health care 
workers [153-155]. House-to-house campaigns can increase vaccination coverage 6-12% 
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compared to fixed vaccination sites. The Measles and Rubella Global Strategic Plan 2012-
2020 Midterm Review states that these campaigns have the potential to increase coverage 
levels above herd immunity (>95%), thus enabling elimination goals to be achieved [49].  
Current measles and rubella (MR) vaccination strategies, utilizing needle-and-
syringe delivery with lyophilized vaccine in multi-dose vials, face numerous logistical 
challenges that limit the execution of house-to-house campaigns needed to reach 
programmatic vaccine coverage goals. First, the vaccine vials, reconstitution media vials, 
syringes, and needles must travel to remote vaccination sites. The vaccine must be kept 
between 2 and 8˚C throughout this journey to prevent viral activity loss [55]. Multi-dose 
vials cost less per dose and require less space in the cold chain, but account for significantly 
more vaccine wastage due to mishandling or excess [156]. By some estimates, 
approximately half of vaccine delivered to developing countries must be discarded due to 
cold chain breaks and wastage from multi-dose vials [138, 157]. During vaccination, 
trained health care workers (HCW) are required to administer the vaccine, placing a 
significant strain on the human resources necessary for vaccinations [49]. The 
reconstitution step adds potential error to ensure the proper volume is added without heat 
shock due to warm reconstitution media [31, 138]. Recently, fifteen children died in South 
Sudan due to measles vaccine reconstitution errors [38]. Finally, after vaccination, HCWs 
must safely dispose of used needles and syringes. Approximately three million HCWs are 
injured due to contaminated sharps each year, leading to 15,000 new cases of hepatitis C; 
70,000 cases of hepatitis B; and 500 cases of human immunodeficiency virus [35-37]. 
These factors indicate the need to improve vaccine delivery technology in order to increase 
MR vaccination coverage.  
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Here, we introduce microneedle (MN) patches as a novel method to administer MR 
vaccine [5, 26, 158-160]. MN patches consist of an array of solid MNs, each several 
hundred microns tall. These MNs are made of vaccine encapsulated in water-soluble 
polymers, sugars and other excipients in a formulation that is strong enough to pierce the 
skin, where the MNs dissolve to release their vaccine cargo [10, 11, 115]. MN patches offer 
numerous benefits to vaccination campaigns. In particular, the patches are small in size 
(e.g. 1 cm2) and do not require reconstitution media. Because the vaccine is in a dry state, 
encased in stabilizing excipients, patches can be stored at ambient or elevated temperatures 
for long periods of time without loss of vaccine potency [9, 28, 88, 161]. Patches can be 
administered by minimally trained personnel or even self-administered and are strongly 
preferred by patients over hypodermic injection [16, 33, 162]. Finally, because MNs 
dissolve in the skin, used patches cannot be reused and pose no risk of needle-stick injury 
to the patient or healthcare worker [26].  
Maternal antibodies present another challenge to measles elimination. Infants of 
vaccinated or naturally-exposed mothers have high levels of circulating anti-measles 
antibodies that wane over the first six to nine months of life [80, 81, 163]. These maternal 
antibodies inhibit development of long-lasting immune response following vaccination 
[78, 164], and the time between low antibody titers and vaccination leaves infants 
susceptible to measles infection. Due to herd immunity present in developed countries, 
vaccination of infants can be delayed until 12-15 months of age, leading to a 95% 
seroconversion rate. In developing countries where infants are vaccinated at 6-9 months, 
the seroconversion rate is much lower at approximately 60% [80]. Therefore, elimination 
campaigns would greatly benefit from a novel vaccine technology that would allow 
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administration within the first six months of life, ideally at birth. MN patches deliver 
vaccines to the skin, an organ rich in resident antigen-presenting cells, such as Langerhans 
cells [5, 26, 158-160]. Intradermal vaccinations have been shown to exhibit dose sparing 
[41, 43, 44] and strong immune responses in vulnerable populations [42, 45, 165]. We 
hypothesize that skin vaccination with a MN patch can induce a potent immune response, 
potentially overcoming maternal antibodies.  
In our previous work, MN patches loaded with measles vaccine were shown to be 
immunogenic in cotton rats and juvenile rhesus macaques, and exhibited no loss of potency 
when stored at 25˚ C with desiccant for up to four months [20, 88]. A key highlight of the 
Midterm Review is the incorporation of rubella vaccines into routine measles vaccinations. 
MR vaccine patches have not yet been fabricated or tested for immune response or 
thermostability. Furthermore, the immune response to any vaccine administered by MN 
patches has not been studied before in infant rhesus macaques. Infants have less developed 
immune systems and have been shown to develop lower antibody titers and avidity, 
compared to their juvenile counterparts [163, 166]. Finally, MN patches have not been in 
the presence of maternal antibodies, naturally occurring or mimicked using an infusion of 
measles immunoglobin [84].  This study sought to address these issues by studying the 
immune response to MR vaccination using a MN patch in juvenile and infant rhesus 
macaques.  
4.2 Materials and methods  
4.2.1 Vaccines 
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The Edmonston-Zagreb vaccine strain for measles and the RA-27 rubella vaccine 
were obtained from stocks at the CDC. Vaccines were passaged in Vero cells (ATCC, 
CCL-81, Manassas, VA) maintained in Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco, Grand Island, NY) and 2% fetal bovine serum (FBS, Gibco). Infected cells were 
harvested, freeze-thawed, and subject to low-speed centrifugation to separate the virus 
from cellular debris. Vaccine aliquots were stored at -80°C [20].  
4.2.2 Production of MN patches  
MN patches were prepared as previously described [9, 88, 167]. Briefly, measles 
vaccine, rubella vaccine and an excipient solution of sucrose, threonine, and 
carboxymethylcellulose (CMC, Sigma-Aldrich, St. Louis, MO) in potassium phosphate 
buffer (pH 7.5) were mixed and placed on a polydimethyl siloxane micromold with 
vacuum. The vaccine solution was allowed to dry into the tips of the MN cavities, and 
residual material on the micromold surface was removed via tape-stripping. A solution of 
polyvinyl alcohol (Acros Organics, Geel, Belgium), sucrose, and DI water was added. 
After two days in a desiccator at room temperature (20 – 25°C), MN patches were 
demolded and stored desiccated at room temperature until use.  
To measure the efficiency of delivery, MN patches were inserted into pig skin ex 
vivo for 20 min to allow complete dissolution of the MNs. The skin was stained with 
gentian violet (Humco, Texarkana, TX) to visualize puncture holes. Viral titers were 
measured in fresh and used patches the difference in titers before and after insertion was 
used to estimate the delivered dose. 
4.2.3 Stability of MN patches 
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MN patches were sealed in aluminum foil pouches (Oliver-Tolas Healthcare, Grand 
Rapids, MI) with desiccant. Pouches were stored in Model 6020 environmental test 
chamber at 40°C (Caron, Marietta, OH) for one month. At various time points, patches 
were removed from the chamber, and viral tires were measured.  
To determine measles vaccine titer, tenfold dilutions of vaccine were inoculated 
onto confluent monolayers of Vero cells in DMEM with 2% FBS. Five to seven days later, 
cytopathic effect was detected after incubation with crystal violet. Titers were determined 
using the Spearman & Karber algorithm as previously described [141]. To determine 
rubella vaccine titer, vaccine was incubated for one hour with anti-measles IgG (EMD 
Millipore, Billerica, Massachusetts) at 37°C to inhibit measles vaccine infection. Tenfold 
dilutions of the vaccine-measles IgG solution were incubated on confluent layers of Vero 
cells for one hour at 37°C. A mixture of DMEM, avicel (FMC BioPolymer, Newark, DE) 
and FBS were added to each well. After three to five days of incubation, cells were fixed 
with methanol, incubated with E1 antibody, HRP-tagged antibody, and 
tetramethylbenzidine sequentially (NeA-Blue TMB substrate, Clinical Science Products, 
Mansfield, MA). Foci were counted using an ELISPOT analyzer (CTL, Cleveland, OH). 
4.2.4 Juvenile rhesus macaques  
Colony-bred macaques were housed at the CDC Animal Facility. At approximately 
two years old, the hair on a region on the back of each macaque was removed with clippers 
and Nair (CVS Pharmacy, Woonsocket, RI). Patches were inserted with the thumb without 
any external device. The patch was pressed into place for 30 sec and allowed to dissolve 
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for 15 min. For the SC group, the vaccination occurred in approximately the same region 
of the back. Serum was collected weekly for eight weeks.  
4.2.5 Infant rhesus macaques 
Colony-bred infant macaques used in the present study were housed at the 
California National Primate Research Center in accordance with the regulations of the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
Standards. The Institutional Animal Use and Care Committee of the University of 
California, Davis, the Georgia Institute of Technology, and the Centers for Disease Control 
and Prevention approved these experiments. Infant macaques were co-housed with measles 
and rubella sero-negative dames and weaned 42 days ( 5 days) prior to vaccination. 
Animal vital signs were regularly monitored. For blood collection and virus inoculation, 
animals were anesthetized with 10 mg/kg ketamine hydrochloride (Parke-Davis, Detroit, 
MI) injected intramuscularly.  
4.2.6 Infant rhesus macaque immunization, inoculation, and sample collection 
Sixteen infant macaques (18-49 days old; mean body weight 0.5 kg) were assigned 
to one of four experimental groups (Table 4). As previously described [86], 4 ml measles 
immunoglobulin (MiG) were administered to two groups at a mean of 32 days ( 9.6 days) 
after birth and 48 hrs prior to vaccination. MiG-treated and untreated groups were 
administered MR vaccination by either subcutaneous injection (SC) or MN patch. For MN 
vaccination, patches were pressed onto the skin, and gentle pressure was applied for 30 
sec. Patches were then left on the skin for 15 min to allow for MN dissolution.  Serum 
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samples were collected every two weeks post vaccination (PV), except at 8, 16, and 26 
weeks PV, when heparinized blood samples were collected.  
At week 28 PV (week 0 post challenge, PC), all vaccinated infant macaques in 
addition to an unimmunized group of macaques (means age 365 days) were challenged by 
intranasal inoculation with measles virus MV12 1x106 TCID50/ml grown in a Vero cell 
line. The derivation of the viral stock for the challenge is described in the Supplemental 
Methods. In methods previously described [86], nasopharyngeal washes and heparinized 
blood samples were collected on 0, 1, 2, 3, 4, 5, 8, and 12 weeks PC. Peripheral blood 
mononuclear cells (PBMCs) were obtained from all macaques on the day of challenge (day 
0), and 7, 14, and 21 days after challenge. 
4.2.7 Serologic methods  
Serum antibody titers were determined using commercial ELISA kits: Measles IgG 
(Serion ELISA classic- Measles IgG, virion\serion, Würzburg, Germany), Measles IgM 
(Serion ELISA classic- Measles IgM, virion\serion), and Rubella IgG (Zeus ELISA IgG 
Test Kits, Branchurg, NJ).  
Neutralization antibody titers to measles were determined using the standard plaque 
reduction neutralization (PRN) assay [168], and antibody titers were determined based on 
Third WHO International Standard Reference Serum (97/648).  Neutralizing antibodies to 
rubella were measured using a focus-reduction assay as described previously [70]. A value 
of 1 IU/ml was assigned to all serum samples with titer less than 5 IU/ml. 
4.2.8 PBMC Analysis  
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Measles viremia was measured by co-culturing dilutions of PBMCs with Raji cells 
as previously described [169]. In addition, the copy number of measles RNA in 
cryopreserved PBMCs was measured by modification of a previously described RT-qPCR 
assay [170].  Briefly, 105 PBMCs were thawed and centrifuged at 1500xg for 5 min, and 
RNA was extracted by using a RNeasy Micro Kit (Qiagen, Hilden, Germany). cDNA was 
prepared using random hexamer primers (ThermoFisher, Waltham, MA) and SuperScript 
III reverse transcriptase (ThermoFisher) per manufacturer protocol and diluted to 40 µl. 
The measles RNA gene was measured by RT-qPCR as previously described [170].  A 
constitutively expressed reference gene, GAPDH, was quantified to control for 
cellular/RNA input and quality of preparation.  Copy numbers of the RNA coding for the 
measles nucleocapsid (N) gene were determined by interpolation of the average measured 
threshold cycle number onto a standard curve produced with a purified PCR amplicon 
containing a fragment of the N gene.    
4.3 Results  
4.3.1 Fabrication of microneedle patches  
The MN patches used in this study consisted of an array of 100 MNs in a 10x10 
grid of approximately 1 cm2 mounted on a backing structure to facilitate handling (Figure 
4.1a). The MNs were solid, conical structures made of water-soluble excipients and 
contained at least 1000 TCID50 of measles and rubella vaccine (Figure 4.1b). The MN 
patches could be pressed onto the skin and, upon penetration into skin, the MNs dissolved, 
leaving behind only the base structure on which they were mounted (Figure 4.1c). The MN 
patches were thermostable (Figure 4.1d); when stored for up to one month at 40°C, there 
 50 
was no significant loss of vaccine potency, which exceeds the WHO requirement for 
stability at 37°C for one week [51, 52]. For future use in vaccination campaigns, a 
packaging concept was developed in which MN patches were housed on blister trays 
housed in cardboard boxes (Figure 4.1e). In this configuration, each single-dose MN patch 
required 10 cm3 of packaged volume and 4 g of packaged weight.  
 
Figure 4.1. Measles-rubella vaccine microneedle patch.  
Microneedle (MN) patches consist of micron-scale projections encasing measles and 
rubella (MR) vaccine in water-soluble excipients. (a) The MN array is 1 cm2, and the 
entire patch is 3.5 cm by 2 cm in size. (b) The MNs are 700 µm long, and (c) once 
inserted, the needles dissolve completely, leaving only a blunt base structure and 
generating no sharps waste. (d) MN patches were stored at 40˚C for up to one month 
without significant loss in vaccine activity. Data show mean titer ± SD (n= 4 
replicates). (e) A box containing 50 doses of MR vaccine is shown next to a 1 mL 
syringe. 
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4.3.2 Juvenile rhesus macaque vaccination with a microneedle patch  
Juvenile rhesus macaques, approximately two years old, were vaccinated via MN 
patch or SC injection. Mild, transient erythema was noted for a few hours after MN patch 
administration; no adverse effects were noted at any point during the study. The humoral 
response was studied at day 0, 28, and 56 after vaccination. Vaccination with MN patch or 
SC injection induced measles neutralizing antibodies and measles-specific IgG titers; no 
statistically significance between the immune responses is noted (Figure 4.2).  
 
Figure 4.2. Juvenile rhesus macaque response to measles vaccination. 
Measles antibody titers following vaccination of juvenile rhesus macaques with a 
microneedle (MN) patch or subcutaneous (SC) injection. Measles-specific 
neutralizing antibodies were measured on day 0 (circle), day 28 (square), and day 56 
(triangle). The height of the bars is the median for the group, while the dash 
represents the mean +/- standard deviation. Vaccination by either vaccination route 
generated equivalent antibody titers. 
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Rubella neutralizing antibodies and rubella-specific IgG titers were determined at 
day 0, 28, and 56 post-vaccination (Figure 4.3). All titers increased after vaccination. At 
both post-vaccination time point, all juvenile rhesus macaques had protective neutralizing 
antibody titers of ≥10 IU/ml. The antibody titers were equivalent between the MN patch 
and SC injection group. Thus, MR can safely be delivered in a MN patch; MN patch 
vaccination induces a comparable immune response to SC injection.  
 
Figure 4.3. Juvenile rhesus macaque response to rubella vaccination. 
Rubella antibody titers following vaccination of juvenile rhesus macaques with a 
microneedle (MN) patch or subcutaneous (SC) injection. (a) Rubella-specific 
neutralizing antibodies and (b) rubella-specific IgG were measured on day 0 (circle), 
day 28 (square), and day 56 (triangle). The height of the bars is the median for the 
group, while the dash represents the mean +/- standard deviation. All juvenile 
macaques had neutralizing antibody titers above the protective threshold (≥10 
IU/ml). Vaccination by either vaccination route generated equivalent antibody titers. 
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4.3.3 Vaccination with a microneedle patch in infant rhesus macaques  
  Rhesus macaques, born to measles-naïve mothers, were vaccinated at 3-4 weeks of 
age (Table 4). MN patches were manually applied to the inner thigh of the macaques and 
left in place for 15 min to allow dissolution (Figure 4.4a). Immediately after removal, an 
array of puncture marks corresponding to the sites of MN puncture were detected on the 
skin (Figure 4.4b), but they were not visible 1 hour after vaccination. Additionally, only 
very mild, transient erythema and no edema or bleeding were observed; no adverse effects 
were noted at any point during the study.  
 
Figure 4.4. Microneedle patches inserted into infant rhesus macaque. 
Microneedle patches (a) were applied to the inner thigh of infant rhesus macaques. 
(b) Immediately after removal, a grid pattern can be seen on the leg due to tiny 
punctures from each microneedle. After a few minutes, this grid pattern disappeared 
(not shown). Very mild, transient erythema, but no edema or bleeding were observed 
following removal of the patch. 
In the groups that did not receive MiG (Figure 4.5, Table 4), the titers of 
neutralizing antibody to measles increased after vaccination, and at day 42, 100% of infant 
rhesus macaques in the MN patch group had protective titers of >120 mIU/ml, while 50% 
of rhesus macaques in the SC group had protective titers. On the day of challenge, all of 
the macaques in the MN group and 75% of the macaques in the SC group had protective 
titers (data not shown).  The failure of one of the macaques in the SC group to seroconvert 
is unclear though previous studies have shown 75-80% of rhesus macaques vaccinated by 
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the SC route generated protective titers [82, 85]. Overall, these data indicate that 
vaccination by MN patch induced a neutralizing antibody response that was at least 
equivalent to the response induced by SC injection in naïve infant macaques.  
In contrast, infant macaques vaccinated by MN patch or SC injection after receiving 
MiG failed to generate protective neutralizing antibody responses to measles by day 42 
(Figure 4.5, Table S1). In these groups, the input MiG was detected by both PRN (Figure 
4.5) and EIA (data not shown) on day 42. Previous studies showed that MiG can be detected 
in infant macaques for up to 8-10 weeks after administration [82, 84]. All of the macaques 
in the MiG treatment group were seronegative for measles as tested by PRN and EIA on 
the day of challenge approximately 30 weeks after MiG administration (data not shown).  
 
Figure 4.5. Measles neutralizing antibody titers. 
Measles antibody titers following vaccination of infant rhesus macaques with a 
microneedle (MN) patch or subcutaneous (SC) injection in the absence or presence of 
measles immune globulin (SC+MIG, MN+MIG). Measles-specific neutralizing 
antibodies were measured on day 0, day 28, and day 42. The bars represent the mean 
neutralizing antibody titer of each group; dots represent titers for each rhesus 
macaque. The dotted line indicates the minimum protective titer of 120 mIU/ml. 
Protective titers of neutralizing antibodies were present in the MN and SC groups; 
vaccination by either vaccination route was unable to generate protective antibody 
titers after pre-administration of MiG. 
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The presence of measles-specific MiG had no effect on rubella vaccination. In both 
the presence and absence of MiG, all of the infant macaques had protective titers of 
neutralizing antibodies to rubella on day 42 (Figure 4.6a). Additionally, all titers were 
substantially above a protective titer of 10 IU/ml. Rubella IgG titers were equivalent across 
all groups at day 28 following vaccination (Figure 4.6b). In general, rubella neutralizing 
antibody titers were higher after MN patch vaccination compared to SC injection, but these 
differences were not significant. Overall, these data show that MiG inhibited the generation 
of an immune response to measles vaccines given by the SC or intradermal routes and that 
rubella vaccination by MN patch or SC injection induced robust neutralizing antibody 
responses.  
 
Figure 4.6. Rubella antibody titers. 
 56 
Rubella antibody titers following vaccination of infant rhesus macaques with a 
microneedle (MN) patch or by subcutaneous (SC) injection in the absence or presence 
of measles immune globulin (MN+MiG, SC+MiG). (a) Rubella-specific neutralizing 
antibodies were measured on day 42. The bars represent the mean neutralizing 
antibody titer of each group; dots represent titers for each rhesus macaque.  Dashed 
line indicates the protective titer of 10 IU/ml.  (b) Rubella-specific IgG antibodies were 
measured on day 0 and day 28. Protective titers of IgG were present in the SC, MN, 
MN+MiG, and SC+MiG groups. The presence of MiG did not affect the response to 
rubella vaccine. Circles indicate titer for each macaque, while the bars indicate the 
mean within the group. 
4.3.4 Measles challenge  
Approximately seven months after vaccination, all groups, as well as four 
unimmunized controls, were challenged intranasally with wild-type measles virus.  All of 
the infant macaques vaccinated in the absence MiG showed no clinical signs of infection 
such as coughing or rash, except for the one macaque in the SC group that failed to 
seroconvert (data not shown).  Infant macaques vaccinated with MN patches no detectable 
viremia as measured by detection of infectious measles virus or viral RNA in PBMCs 7 
and 17 days after challenge (Figure 4.7). Other than the infant rhesus that failed to 
seroconvert, all macaques in the SC injection group had no detectable infectious measles 
virus in their PBMC, though a low level of measles RNA was detected in one macaque 
(Figure 4.7). Therefore, vaccination of infant macaques with a MN patch induced a 
protective immune response, which was at least comparable to the protection provided by 




Figure 4.7. Measles response to challenge. 
Vaccination with an MR vaccine by microneedle patch (MN) or by subcutaneous in 
(SC) protects infant rhesus macaques from challenge with wild type measles virus. At 
202-216 days (mean 212 days, mean age 244 days) after vaccination, all vaccinated 
macaques and four naïve controls (means age 365 days, unimmunized) were 
challenged with 1 x 105 TCID50 by the intranasal route. PBMCs were obtained from 
all macaques on the day of challenge (day 0), as well as 7, 14, and 21 days after 
challenge. Measles viremia was measured by co-culturing dilutions of PBMCs with 
Raji cells and extracting RNA from PBMCs and conducting RT-qPCR to determine 
the number of copies of measles RNA in each sample. Results are expressed as (a-c) 
mean log10 TCID50 of measles virus or (d-f) mean log10 copies of measles RNA per 106 
PBMCs.  In the absence of MiG, all macaques vaccinated with the MN patch and 
three of four macaques vaccinated by SC injection were protected from challenge. 
Infant rhesus macaques that were vaccinated in the presence of measles immune 
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globulin (MN+MiG, SC+MiG) and one macaque in the SC group that did not have a 
protective titer were not protected from challenge. 
All eight infant rhesus vaccinated in the presence of MiG displayed clinical signs 
of infection which were comparable to those of the unimmunized controls (data not 
shown). All of the macaques had viremia as measured by detection of infectious measles 
virus and measles RNA in PBMCs at days 7 and 14 after challenge. The viral titers and 
copy number of measles RNA in macaques vaccinated in the presence of MiG were similar 
to those of the unimmunized controls (Figure 4.7).  
 
Figure 4.8. Humoral response to challenge. 
Serologic response to measles virus following challenge with wild-type measles virus 
in infant rhesus macaques previously vaccinated against measles and rubella with a 
microneedle (MN) patch or by subcutaneous (SC) injection. All vaccinated macaques 
were challenged with 1 x 105 TCID50 of measles virus by the intranasal route 202–216 
days (mean 212 days, mean age 244 days) after vaccination. (a) Means measles-
specific neutralizing antibody titers are shown as bars and titers for each rhesus are 
shown as dots. The horizontal dashed line indicates a protective titer of 120 mIU/ml. 
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(b) Measles-specific IgM titers were measured on the day of challenge (day 0, light 
gray bar), as well as day 7 (medium grey bar) and day 14 (dark grey bar) days after 
challenge. All macaques in the MiG treatment group seroconverted to measles by day 
14, and all had an IgM response. 
In the macaques vaccinated in the presence of MiG, protective neutralizing 
antibody titers were detected in all of the macaques by day 14 after challenge, and the titers 
of neutralizing antibodies boosted in all the macaques vaccinated in the absence of MiG 
(Figure 4.8a).  With the exception of the macaque from the SC group that failed to 
seroconvert to vaccination, there was no measurable IgM following challenge in the 
macaques vaccinated in the absence of MiG (Figure 4.8b). However, all of the macaques 
vaccinated in the presence of MiG had an IgM response by day 14 after challenge 
suggestive of a primary immune response to measles (Figure 4.8b).   
4.4 Discussion  
4.4.1 MR vaccination by microneedle patch is immunogenic in rhesus macaques 
In this study, we developed MN patches that administer both measles and rubella 
vaccines in a single dose.  Juvenile rhesus macaques generated virus specific antibodies to 
both vaccines. The antibody titers were equivalent those receiving a SC injection. In naïve 
infant rhesus macaques, vaccination via MN patches induced a potent immune response to 
both measles and rubella vaccines. Measles- and rubella-specific neutralizing antibodies 
were well above protective titers of 120 mIU/ml and 10 IU/ml, respectively. Additionally, 
virus-specific IgG titers after MN patch vaccination were statistically indistinguishable 
from those of monkeys vaccinated via SC injection. Following challenge with live measles 
virus, vaccinated animals had strong neutralizing antibody titers rapidly boosted by the 
viral challenge (without generation of IgM) and showed no clinical signs of infection (e.g., 
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rash), viremia or presence of measles viral copies. These data combined indicate that MN 
patches can effectively vaccinate infants and induce an equivalent protective immune 
response to traditional needle and syringe injection.  
4.4.2 Microneedle patch can improve vaccination coverage  
Improved MR vaccination coverage is crucial to meeting elimination goals. The 
traditional needle-and-syringe method for delivering vaccinations faces numerous 
challenges, particularly when used for MR elimination and future eradication efforts 
involving mass vaccination, ideally conducted house-to-house [124]. First, current 
vaccines are available in multi-dose lyophilized vials which necessitate storage in the cold 
chain, reconstitution before injection, and discarding vaccine if not used within 6 hours of 
reconstitution [32]. The vaccine is then injected SC by a trained health care provider, who 
must properly dispose of the hypodermic needle sharps waste to avoid re-stick injuries and 
disease transmission. An alternative vaccination method could increase vaccination 
coverage by easing the logistics and reducing costs for vaccinations [126, 171].  
In this work, we developed a MN patch designed to overcome many of the logistical 
barriers associated with traditional MR vaccination. MN patches have a single-dose 
presentation, which reduces vaccine wastage associated with multi-dose vials. Because the 
patches are administered in a dry state, no vaccine reconstitution is needed, which avoids 
the expertise needed to reconstitute vaccine, eliminates errors associated with incorrect 
reconstitution and gets rid of the additional vials and syringes needed for the reconstitution 
process. Also, because MN patches require no water or syringes for injection, they have a 
much smaller packaged volume and weight, thereby facilitating transportation, storage and 
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waste disposal, which can be important in mass vaccination campaigns, especially when 
involving access to remote locations.  
Through improved formulation and fabrication, MN patches can be stored at 
elevated temperatures for at least one month without loss of activity, thereby saving on 
refrigeration costs and reducing vaccine wastage associated with cold-chain failures [158]. 
Because MN patches are simple to administer, they can be used for MR vaccination by 
minimally trained personnel, an attribute that has been critical to smallpox and polio 
eradication programs in developing countries where expert health care personnel are in 
short supply. Finally, MN patches are expected to be inexpensive to manufacture and have 
been shown to be effective for delivery of a variety of vaccines [5, 26, 158-160], including 
prior studies of measles vaccination in cotton rats and juvenile rhesus macaques [20, 88] 
and a recent human clinical trial of influenza vaccination [16]. 
Jet injectors, which utilize a stream of liquid at a high pressure to pierce through 
skin, is a needle-free vaccination method that has attracted interest because it does not 
generate biohazardous sharps waste; however, the administration of these injectors requires 
training and offers no benefits for thermostability. In adults and toddlers, measles-mumps-
rubella (MMR) vaccination with a jet injector induced an immune response comparable to 
traditional needle-and-syringe injection, but had significantly higher pain scores [58, 59]. 
However, in another MMR vaccination study, the jet injector induced inferior measles and 
mumps antibody titers but equivalent rubella antibody titers compared to SC injection in a 
clinical trial in infants [60]. The low measles titers were attributed to incomplete delivery 
when using the jet injector.  
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Another alterative mode of measles vaccination involves delivery of aerosolized 
vaccine by inhalation [64, 67]. While inhaled measles vaccine in schoolchildren compared 
favorably to SC injection in one study, another study in infants showed inferior immune 
responses compared to SC injection [64, 67]. Clinical studies in adults have demonstrated 
the safety of aerosol vaccination [65, 66]. The immune response was comparable to SC 
injection; however, because all subjects were measles positive initially, the immune 
response in a naïve patient was unclear.  
There has been limited prior attention to measles and rubella vaccination in the 
skin, other than our work on MN patch vaccination [20, 88]. One study utilized tape 
stripping to remove the outer layers of the skin followed by topical inoculation with 
measles vaccine. However, the serology showed an inferior response compared to a SC 
injection [57]. 
4.4.3 Maternal antibodies hinder vaccination  
The presence of maternal antibodies hinders efforts to vaccinate infants early in life; 
this window of susceptibility accounts for approximately 20% of cases worldwide [163]. 
Maternal antibodies wane between 6 to 9 months of age; infants vaccinated during this 
time seroconvert 60% of the time, compared to 95% of infants vaccinated between 12 and 
15 months [81, 82]. Previous work has studied approaches to allow for earlier vaccination 
in the presence of maternal antibodies. For example, DNA vaccines were only able to 
produce a protective response when co-administered with IL-2 molecular adjuvant [85, 
87]. However, use of this adjuvant may raise safety concerns. Here, we hypothesized that 
the heightened immune responses sometimes associated with skin vaccination could enable 
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measles vaccination via a MN patch to overcome the inhibitory effects of MiG. However, 
the resulting immune response was not strong enough to protect these animals from 
challenge. More work to develop more potent vaccines, adjuvants and delivery methods 
will be necessary to enable vaccination closer to the time of birth.   
4.5 Conclusion  
Measles and rubella control programs need higher levels of vaccination rates to 
achieve elimination goals. At the 2016 Global Vaccine and Immunization Research forum, 
public health officials emphasized the critical need for novel vaccine delivery tools, and 
that these tools could represent a “potential game-changer” for eradication efforts [133, 
171].  MN patches may provide a MR vaccination method that addresses these needs; 
however, in previous MN patch studies, MR vaccination and thermostabilization have not 
been studied before, administration of any vaccine to infant primates has not been 
investigated, and the ability of skin vaccination by MN patch to overcome MiG has not 
been assessed.  
To address these needs, this study developed MN patches for MR vaccination with 
attributes designed to offer significant benefit over traditional needle-and-syringe delivery 
techniques, especially for vaccination campaigns. The MN patches have a single-dose 
presentation requiring no reconstitution, which should reduce vaccine wastage, and 
enabling at least partial removal from the cold chain. They are simple to administer and 
generate no sharps waste, suggesting their suitability for administration by minimally 
trained personnel. Their small size and weight, in addition to expected low cost of 
manufacturing, are additional attributes of interest. In animal studies, the MN patches were 
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well-tolerated in juvenile and infant rhesus macaques; only mild, transient effects were 
seen at the MN patch application site and no long-term adverse effects over the course of 
the study were noted. Immunologically, MR vaccination by MN patch in infant macaques 
was not significantly different from SC injection of the vaccine and provided strong 
neutralizing antibody responses that protected animals from live measles virus challenge. 
However, MN patch vaccination could not generate protective immune responses in 
monkeys with MiG to simulate maternal antibodies. Overall, we conclude that MR 
vaccination using MN patches offers superior attributes important to mass vaccination with 
similar immunological outcomes. In this way, MN patch vaccination can enable increased 
vaccination coverage that is critical to MR elimination efforts.    
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CHAPTER 5. EXTENDED DELIVERY OF VACCINES TO THE 
SKIN IMPROVES IMMUNE RESPONSE   
Vaccines prevent 2-3 million childhood deaths annually; however, low vaccine 
efficacy and the resulting need for booster doses creates gaps in immunization coverage. 
Here, we explore the benefits of extended antigen release into skin to increase immune 
responses after a single dose. By administering daily intradermal injections of inactivated 
polio vaccine according to six different profiles, zeroth-order release over 28 days resulted 
in neutralizing antibody titers equivalent to two bolus vaccinations administered one month 
apart. Vaccinations following this profile also improved immune responses to tetanus 
toxoid and subunit influenza vaccine but not measles vaccine, which naturally persists in 
the body as a live-attenuated virus. Finally, using subunit influenza vaccine, we 
demonstrated that daily vaccination by microneedle patch induced a potent, balanced 
humoral immunity with an increased memory response compared to bolus vaccination. We 
conclude that extended presentation of antigen in skin via intradermal injection or 
microneedle patch can enhance immune responses and reduce the number of vaccine doses, 
thereby enabling increased vaccination coverage.  
5.1 Introduction  
Vaccines are lauded as one of the top ten public health interventions of the past 
century [1], with immunizations resulting in the prevention of 2-3 million childhood deaths 
annually [172].  However, an additional 1.5 million deaths occur due to lack of adequate 
vaccination coverage [172]. In developing countries, vaccinations are often provided by 
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mass vaccine campaigns that include fixed clinics as well as trained personnel traveling 
house-to-house to reach remote areas [26]. Despite these efforts, inherent properties of 
vaccines complicate the ability to deliver doses at the appropriate time intervals. 
Additionally, low seroprotection rates require multiple costly, resource intensive 
vaccinations to limit the spread of disease [39]. Children who are immunocompromised by 
inadequate nutrition and co-existing infections seroconvert at rates lower than would be 
expected [26, 173, 174]. Furthermore, the majority of vaccines recommended by the WHO 
Expanded Programme on Immunization are delivered by hypodermic needle and syringe 
[175]. This creates a requirement of trained healthcare providers to deliver injections and 
dispose of the needles safely to prevent transmission of blood-borne pathogens.  
Revamping vaccine technology to increase vaccine immunogenicity, reduce the number of 
vaccinations and simplify the vaccination method could lead to increases in immunization 
coverage.  
One strategy to increase the immune response to vaccination is prolonging antigen 
presentation [39]. There are two major categories of vaccines: live-attenuated vaccines and 
killed/subunit vaccines. The former, such as measles, smallpox, and varicella, mimic 
immunity that results from infection and can provide lifelong protection after a single 
administration. However, the majority of vaccines belong to the latter group and require 
one or more booster administrations separated by months or years to produce lasting 
immunity [176]. Extended delivery of an antigen can mimic a natural infection’s kinetics, 
thereby generating a much stronger immune response to the same dose. However, common 
approaches to utilize controlled release systems follow kinetics with a large burst, followed 
by low levels of antigen release. While these systems do improve the immune response, 
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other profiles may allow for a stronger response. Johansen et al. delivered gp33 and CpG 
to vaccinate against lymphocytic choriomeningitis virus. They compared exponentially 
increasing, exponentially decreasing, constant, and bolus injections over 4 days delivered 
by daily injection. They report significantly higher levels of CD8+ active T cells in the 
exponentially increasing group, likely due to the mimicked kinetics to a replicating 
pathogen [177]. In an in vitro study, dendritic cells released higher levels of IL-2 and IL-
10 cytokines when stimulated in an exponentially increasing fashion [177]. Other studies 
have replicated this finding and demonstrated increased antigen capture and retention in 
lymph nodes is responsible for the increased antibody response [109, 113]. Thus, the 
literature suggests that extended presentation of some model antigens can increase immune 
responses. However, studies are needed that use licensed vaccines, conduct a detailed 
examination of antigen delivery profiles, and determine if a single dose of vaccine 
delivered over an extended time can provide protective immunity comparable to that after 
a two-dose prime-boost schedule.  
Intradermal (ID) delivery can improve immune responses. The skin, unlike muscle 
and subcutaneous space, is an immunological organ with roles in both innate and adaptive 
immunity [26]. The epidermis is largely composed of keratinocytes, expressing a variety 
of receptors specialized in recognizing pathogen-associated molecular patterns and 
bacterial, fungal, and viral antigens [178]. Antigen-presenting cells, such as epidermal 
Langerhans cells and dermal dendritic cells, can effectively capture, process, and present 
antigens. APCs can then travel to nearby lymph nodes, activating the adaptive immune 
response [179, 180]. Studies have demonstrated more efficient antigen migration into 
draining lymph nodes than intramuscular injections [181]. Additionally, higher levels of 
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activated T follicular helper cells (TFH) and germinal center B cells (GC B) were identified 
in lymph nodes following skin vaccination [45]. By delivering antigen directly to the skin, 
intradermal vaccination enhances immunogenicity, and can thereby reduce the number of 
doses needed to seroconvert or result in significant dose-sparing of vaccines. This effect 
was seen in several different applications, including smallpox [182], rabies [183], and 
influenza [184].   
While ID vaccination offers improvements to the immune response, delivering 
antigen into the skin is difficult. The Mantoux technique, in which the needle is inserted at 
a shallow angle, requires special training to reliably target the skin [185]. Dissolving 
microneedle (MN) patches are an emerging technology for ID vaccinations [5, 28, 158-
160]. MN patches are an array of polymer needles that are less than 1 mm long and fixed 
into a hard backing. The patch can then be painlessly applied to the skin, delivering vaccine 
antigen in a controlled fashion directly into the epidermis and dermis [19, 115, 159, 186]. 
Once the needles dissolve, the needles cannot be reused, and the backing can be discarded. 
Vaccination with MN patches have induced potent immune responses, even demonstrating 
dose-sparing in some cases [41, 43, 44]. Extended release via microneedles has also been 
shown [14, 115, 116]. Patches of silk-tipped MNs delivering whole-protein vaccine 
released over 1-2 weeks resulted in over a tenfold increase in adaptive immune response 
compared to subcutaneous or intramuscular bolus injections [187]. The use of MN patches 
for extended delivery of vaccines has received only limited attention.  
Guided by these studies, we envision a vaccine delivery system that targets antigen 
to the skin and presents that antigen over an extended period of time to improve 
immunogenicity, using a MN patch that simplifies vaccination. Here, we examined the 
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effect of six different extended delivery profiles on immunogenicity using four different 
licensed vaccines administered to the skin. Extended delivery profiles were studied by 
administering multiple fractional vaccine doses given by intradermal injection or 
microneedle patch. In this context, we compared single doses of extended delivery 
vaccination to two-dose bolus vaccination. We showed for the first time that extended 
delivery for one month further improves the immune response compared to extended 
delivery over shorter periods of time. Additionally, extended delivery achieved through 
repeated dissolving MN patch vaccination further increases the immune response 
compared to injections. Future studies will address development of formulations that can 
achieve the optimized delivery profiles after application of a single MN patch.  
5.2 Materials and methods  
5.2.1 Vaccines  
Monovalent stock solutions of types 1, 2 and 3 IPV vaccine were generously 
provided by GlaxoSmithKline Biologics (Rixensart, Belgium). These vaccine antigens are 
the same as those used in Poliorix. Influenza subunit vaccine bulk (A/Brisbane/10/10) was 
generously provided by Seqirus (Maidenhead, United Kingdom). This vaccine antigen is 
the same as that used in the 2015-2016 seasonal vaccine Fluvirin. Tetanus toxoid vaccine 
bulk was kindly supplied by the Serum Institute of India (Pune, India). This vaccine antigen 
is the same as that used in Tetanus Toxoid Vaccine Adsorbed.  The Edmonston-Zagreb 
strain of measles virus vaccine (kindly supplied by the Serum Institute of India) was grown 
in Vero cells maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand 
Island, NY) and 2% fetal bovine serum (FBS, Gibco). At the maximum of the cytopathic 
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effect, cell suspensions were freeze-thawed and centrifuged to eliminate cellular debris, as 
previously described [20]. This measles virus is the same as that used in M-VAC, but 
propagated using Vero cells at CDC rather than in MRC-5 cells at the Serum Institute of 
India. All vaccines were diluted in sterile saline solutions prior to injections.  
5.2.2 Microneedle patch  
MN patches were fabricated as described previously [9, 167]. Briefly, influenza 
vaccine was mixed with 10% w/v sucrose (Sigma Aldrich, St. Louis, MO) and 1% w/v 
sodium carboxymethyl cellulose (250 kDa, Sigma Aldrich) in deionized water. This 
solution was cast onto silicone molds under vacuum and dried. A polymer matrix solution 
of 28% w/w polyvinyl alcohol (78% hydrolyzed, 6 kDa; Acros Organics, Geel, Belgium), 
21% w/w sucrose, and water was added to the mold, dried. MN patches were removed 
from their molds and stored at room temperature (22-25°C) with desiccant until use for 
vaccination. Placebo patches were fabricated with only the polymer matrix solution.  
5.2.3 Animal studies  
On vaccination days, rodents were anesthetized either daily for seven days or every 
other day for fourteen or twenty-eight days. Anesthesia was induced with 5% isoflurane 
and maintained during the procedure at 2%. Animals were then vaccinated by injection in 
the skin using a 28 gauge hypodermic needle by the Mantoux method, in the muscle using 
a 28 gauge hypodermic needles, or by MN patch applied to the skin. All injections 
administered 20 or 100 µL of vaccine containing full or fractional vaccine doses such that 
the cumulative dose received by all animals was the same, as described for each 
experiment. Animals receiving booster doses received a second full dose, such that those 
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animals received a cumulative dose twice that of the non-boosted groups. All doses were 
verified by enzyme-linked immunosorbent assay (ELISA) or end-point titration, in the case 
of measles vaccine [9, 71, 188]. Blood was collected at set time points; serum separator 
tubes (Becton Dickinson, Franklin Lakes, NJ) were used to separate sera during 
centrifugation. All animal studies were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee (IACUC), and IPV vaccination studies were 
also approved by the CDC IACUC.  
5.2.3.1 Inactivated polio vaccine 
For IPV studies, female Wistar rats (Charles River, Wilmington, MA), age 6-8 
weeks, were anesthetized with isoflurane (n=10 per group). Vaccine was diluted in sterile 
saline to the proper concentration. Rats were vaccinated with 100 ul either intradermally 
on the flank or intramuscularly in the thigh. In monovalent IPV studies, all rats received 
IPV type 2 at a cumulative dose of 0.8 D-antigen units (DU). In trivalent IPV studies, rats 
received 10 DU of type 1 IPV, 2 DU of type 2 IPV and 8 DU of type 3 IPV (which is 25% 
of the conventional IPV dose administered to humans [189]) via 100 ul injections. Blood 
was collected from the tail vein via laceration biweekly until day 56 or 84; for the 
longitudinal study, blood draws continued monthly until month 6.  
5.2.3.2 Tetanus toxoid vaccine 
Female Balb/c mice (Charles River, age 6-8 weeks) were vaccinated with tetanus 
toxoid vaccine intradermally at the base of the tail (n = 9 - 10 per group). The cumulative 
dose was 5 flocculation units (Lf) (which is equal to the conventional tetanus toxoid dose 
administered to humans [189]), administered either as a full-dose bolus (in 20 uL) or by 
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1/14th dose (in 20 uL) every other day over 28 days. Blood was collected via the jugular 
vein on days 0, 14, 28, and 42.  
5.2.3.3 Measles vaccine  
Female cotton rats (Harlan, Indianapolis, IN, age 8 weeks) were vaccinated with 
live-attenuated measles vaccine intradermally on the side (n= 10 per group). The total dose 
was 200 50% tissue culture infective dose (TCID50) (which is 20% of the minimum 
conventional measles vaccine administered to humans [20]), administered either as a full-
dose bolus (in 20 uL) or by 1/14th dose (in 20 uL) every other day over 28 days. Blood was 
collected via the jugular vein on days 0, 14, 28, 42, and 56.  
5.2.3.4 Influenza vaccine 
Female Balb/c mice (Charles River), 6-8 weeks of age, were immunized with 
influenza vaccine either via intradermal injection at the base of the tail, intramuscular 
injection in the thigh muscle or microneedle patch on the back (n=8 per group). A 
cumulative dose of 1 µg (which is 7% of the conventional influenza vaccine administered 
to humans [189]) was given either by full-dose bolus (in 20 uL) or by 1/14th dose (in 20 
uL) every other day over 28 days. On day 77, groups that had received bolus vaccination 
were boosted with a second full-dose bolus. Blood was collected via the jugular vein on 
days 0, 14, 28, 42, 56, 77, 91, and 105.  
In a second study, mice were vaccinated ID or by MN patch, receiving 1 ug total 
dose. Blood was collected on days 0, 7, 14, 21, 28, and 35. On day 28, the boost group 
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received another 1 ug by dose ID injection. On day 35, animals were euthanized; spleen, 
lymph nodes, and bone marrow were collected as previously described [190, 191].   
5.2.4 IPV neutralizing antibody assay 
Assay of poliovirus neutralizing antibodies was performed at the CDC Polio and 
Picornavirus Laboratory using their standard protocols [192] . Briefly, diluted serum 
samples were incubated with polioviruses types 1, 2, and 3 (Sabin) at 35°C for three hours 
prior to the addition to HEp-2(C) cells. After incubation for five days at 35°C, cells were 
stained with crystal violet and cell viability was measured by optical density. Titers were 
determined as the reciprocal of the dilution that was able to inhibit 50% of virus binding 
[188, 193]. Seropositivity was defined as antibody titers greater than or equal to 3.0.  
5.2.5 Tetanus toxoid-specific antibody assay 
Tetanus toxoid-specific IgG titers were determined via ELISA, as described 
previously [167] . Briefly, tetanus toxoid was coated on a microwell plate at 0.5 Lf/mL. 
Diluted serum samples followed by HRP- tagged anti-mouse antibody (Southern 
Biotechnology Associates, Birmingham, AL) were allowed to bind to the plate. Optical 
density values were compared to a standard curve of mouse IgG to determine titers.  
5.2.6 Measles neutralizing antibody assay 
Measles titers were determined using a plaque-reduction neutralization assay, as 
described previously [168]. Briefly, diluted serum samples were mixed with measles 
challenge virus (University of California, Davis, CA) and incubated for 2 h at 37°C. The 
samples were then plated onto 24-well plates with a confluent monolayer of Vero cells 
 74 
(American Type Culture Collection, Manassas, VA) and incubated for an additional 2 h at 
37°C, after which an overlay media of 0.8% CMC was added to the cells. Five to seven 
days later, media was removed, and crystal violet solution was added for 20 min. Plaques 
were counted in each well, and titers are determined according to the Third WHO 
International Standard Reference Serum (97/648).  
5.2.7 Influenza hemagglutination assay 
Hemagglutination inhibition (HAI) assay was used to determine influenza-specific 
antibodies as a correlate to immune response, as described previously [194]. Briefly, serum 
was treated with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan) at 37°C 
overnight. The following day, samples were inactivated at 56°C for 30 min. Packed chicken 
red blood cells (Lampire Biological Laboratories, Pipersville, PA) were added and 
incubated with samples overnight. Light centrifugation was used to remove the red blood 
cells. Supernatant was serially diluted in phosphate-buffered saline (PBS). Samples were 
then mixed with A/California/07/2009 influenza virus for 30 min. Red blood cells were 
added and incubated for approximately 10 minutes until the titer at which agglutination 
was inhibited could be determined. The highest dilution titer that inhibited 
hemagglutination was read as the HAI titer. Seroprotection was defined as antibody titers 
greater than or equal to 40.  
5.2.8 Influenza-specific antibody assay 
Purified mouse IgG, IgG1, and IgG2a and goat anti-mouse-HRP were purchased 
from Southern Biotechnology Associates. Titers were determined via ELISA as previously 
described [83]. Briefly, subunit influenza vaccine was coated on microwell plate. Diluted 
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serum samples, horseradish peroxidase (HRP)-tagged antibody, and SureBlue Reserve 
TMB Microwell Peroxidase Substrate (KPL, Gaithersburg, MD) were subsequently added 
to the plate. Once sufficient color had developed, reaction was stopped using TMB 
BlueSTOP Solution (KPL); plates were analyzed using absorbance at 620 nm. 
5.2.9 Cellular analysis  
5.2.9.1 Flow cytometry 
Lymph nodes (LN, inguinal and axillary) were harvested from mice and single cell 
suspensions were prepared and stained with fluorescent anti-mouse antibodies for detection 
of germinal center forming B cells (GC B cell, B220+GL7+), T follicular helper (TFH, 
CD3+CD4+CXCR5+PD1+) and plasma blast (CD3-CD138+) cells by flow cytometry. For 
antibody staining, the cells were incubated with fluorescent anti-mouse antibodies in FACS 
buffer for 30 min at 4°C and washed with FACS buffer and fixed with BD Cytofix. Flow 
data was acquired using a BD LSRII flow cytometer and analysed by Flow Jo software.  
5.2.9.2 ELISPOT assay 
Subunit influenza vaccine specific antibody secreting plasma cells in bone marrow 
was detected by ELISPOT assay. For this, MultiScreen HTS-IP filter 96 well plate 
(Millipore, Billerica, MA) was coated with antigen (1 ug/ml) overnight at 4°C, and next 
day, one million bone marrow cells (collected from femur and tibia) without RBC in 
complete RPMI 1640 cell culture media was added to each well and incubated overnight 
in a 37°C incubator with 5% CO2. Secreted anti-HA-IgG1 and IgG2a were then detected 
by alkaline phosphatase (AP) conjugated goat anti-mouse IgG1 and IgG2a antibodies 
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(Southern Biotech) and finally the antibody spots were developed by Vector Blue AP 
substrate (Vector Laboratories, Burlingame, CA). An ELISPOT reader was used to image 
and count the spots in the well.   
5.2.9.3 Antigen restimulation studies 
Antigen restimulation assay was performed to evaluate antigen specific Th1 immune 
response. For this, single cell suspension of splenocytes was first prepared by collagenase 
digestion of spleen and then one million splenocytes in complete RPMI 1640 media were 
incubated with antigen at 1 ug/ml concentration in a 96 well plate for 72 hrs. IFN gamma 
level in the restimulation media was determined by ELISA using a ready-set-go IFN 
gamma ELISA kit (EBioscience, San Diego, CA).   
5.3 Results  
5.3.1 Optimal delivery profile 
Vaccines are conventionally administered as a bolus. Our initial studies were 
designed to identify the optimal release profile for vaccine delivered into the skin. In order 
to reduce the number of groups and therefore the number of animals, we separated the 
study into two parts: (1) to identify the optimal release profile and (2) to identify the optimal 
length of delivery. First, we studied six different delivery profiles of monovalent type 2 
IPV administered over the course of seven days in order to understand the effect of the 
time course of antigen presentation, as seen in Figure 5.1. A bolus injection served as the 
control of standard vaccinations. Constant and Exponentially Increasing profiles mimic 
natural infection kinetics, where a pathogen persists and in some cases, multiplies over 
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time. An initial prime dose was followed by either a steady decrease in dose (Exponentially 
Decreasing profile) or a constant dose (High/Low profile) to provide a strong initial 
activation of the immune system followed by continued antigen presentation. Finally, the 
Rise/Fall profile provides a more gradual onset and offset of antigen presentation by using 
an exponential increase followed by a decrease in antigen dose over the course of a week. 
The cumulative vaccine dose administered in each of these profiles was held constant at 
0.8 DU.  
 
Figure 5.1. Kinetic profiles. 
Daily intradermal injections were administered over seven days, following six 
different profiles.  
Bolus delivery showed expected neutralizing antibody response over time, with an 
increase and plateau in titers over the course of eight weeks (Figure 5.2a) [195]. 
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Exponential Decreasing, High/Low and Rise/Fall profiles did not yield significantly 
different antibody titers compared to bolus delivery (p>0.90). However, neutralizing 
antibody titers when the dosing followed Constant and Exponentially Increasing delivery 
were significantly greater than bolus delivery neutralizing antibody titers (p=0.011 and 
0.005, respectively). This indicates that it was beneficial to prolong antigen delivery in a 
manner that maintained or increased dose over time, while profiles with an initial burst 
followed by low antigen levels were not beneficial.   
Additional analysis of neutralizing antibody titers on Day 28 (Figure 5.2b) shows 
mean and median antibody titers that were 2-3 fold higher after Constant and Exponentially 
Increasing delivery compared to bolus delivery. Determination of seropositivity (Figure 
5.2c) confirm these findings, showing 60 – 70% seropositivity after Constant and 
Exponentially Increasing delivery compared to only 40% seropositivity after bolus 
delivery. We selected the Constant release profile for further characterization. It appeared 
equivalent to the Exponentially Increasing profile with the added benefit of being easier to 
replicate in future studies.  This profile could more easily be converted to a single-dose, 




Figure 5.2. Release profile over seven days. 
Neutralizing antibody titers over time (a) show constant and exponentially increasing 
profiles induce higher titers compared to bolus vaccination. (b) Titers at day 28 post 
initial vaccination; the dotted line at 2.5 indicated the assay baseline (*p<0.05). (c) 
Seropositivity is the percent of animals in each group with titers >3.0. Total dose was 
10% of a human dose (0.8DU of IPV type 2). 
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5.3.2 Optimal length of delivery and boosting 
Next, we investigated the effect of the total duration of delivery on the immune 
response, and more broadly assessed the effects of extended delivery by administering 
trivalent IPV (i.e., types 1, 2 and 3). Three experimental groups received a single dose 
distributed every day for 7 days, every-other day for 14 days, or every-other day for 28 
days. These results were compared to a single bolus priming dose (Bolus-P) or a two-dose 
prime + boost regimen (Bolus-P+B). Immune response to type 2 IPV was similarly strong 
in all vaccination groups at day 84 following initial dosing (Figure 5.3b). In response to 
type 1 vaccination, 28-day exposure to antigen produced significantly better neutralizing 
antibody responses than a single priming dose and was statistically indistinguishable 
(p=0.999) from the two-dose prime + boost regimen (Figure 5.3a). Neutralizing antibody 
titers to type 3 IPV showed the greatest differences, where 7-day and 28-day extended 
vaccine delivery were superior to a single bolus dose (p=0.035 and <0.0001), and 28-day 
delivery was again statistically indistinguishable from the two-dose prime + boost regimen 
(p=0.999) (Figure 5.3c). Looking at the seropositivity data (Figure 5.4), only 28 days of 
constant dosing and the prime + boost group achieved 100% seropositivity across all three 
serotypes.  This suggests that a single dose of a month-long slow-release formulation of 
IPV can produce immunity similar to a two bolus doses of vaccine.  
 81 
 
Figure 5.3. Duration of release- Titers at day 84. 
IPV type one neutralizing antibodies at day 84 are represented in panel a; IPV type 
two in b; and IPV type three in c (ns- p>0.05; * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001). These data show that extended delivery over 28 days induces neutralizing 
antibody titers equivalent to two doses administered one month apart. Total dose was 
25% of a human dose (10 DU of IPV type 1, 2DU of IPV type 2, and 8 DU of IPV type 
3). 
 
Figure 5.4. Duration of release- Titers over time and seropositivity. 
IPV type one neutralizing antibodies are represented in panels a and d; IPV type two 
in b and e; and IPV type three in c and f. The top row of panels shows the titers over 
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time, with the arrow representing the boost on day 28 and the dotted line representing 
the baseline of the assay. The bottom row shows seropositivity at each time point.  
To further understand the relationship between extended delivery and boosting, rats 
were administered trivalent IPV as a two-dose 7-day extended-delivery regimen to 
combine the benefits of extended delivery and boosting. This approach yielded neutralizing 
antibody titers greater than either a single bolus dose or a two-dose prime + boost regimen, 
which was statistically significant for types 2 and 3 IPV (p= 0.047 and 0.001) (Figure 5.5 
and Figure 5.6). However, the two-dose extended-delivery regimen was not significantly 
different than a single 28-day extended delivery for any of the three serotypes. These data 
indicate that extended delivery can be used to improve either the prime or boost regime.  
 
Figure 5.5. Boosting- Titers at day 56. 
The titers at day 56 for each of the three isotypes of IPV are individually represented 
(* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). Extended delivery over seven days 
during the boost increases immune response compared to bolus delivery for both 
doses. Total dose was 25% of a human dose (10 DU of IPV type 1, 2DU of IPV type 2, 
and 8 DU of IPV type 3). 
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Figure 5.6. Boosting- Titers over time and seropositivity. 
IPV type one neutralizing antibodies are represented in panels a and d; IPV type two 
in b and e; and IPV type three in c and f. The top row of panels shows the titers over 
time, with the arrow representing the boost on day 28. The bottom row shows 
seropositivity at day 56 and day 168 (6 months).   
5.3.3 Effect of route of administration 
To this point, we have identified optimal vaccine kinetics during intradermal 
vaccination. We next examined if the same profile would also be beneficial in the muscle. 
Rats were administered trivalent dose of IPV either intramuscularly (IM) or intradermally 
(ID) and either as a bolus or extended delivery over 28 days. Neutralizing titers against 
type 2 were equivalently high for all groups (Figure 5.7b, p>0.999). In response to type 1 
and 3 vaccinations, there was no statistically significant difference in the immune response 
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between the bolus IM and bolus ID groups, nor was there a difference between the extended 
delivery of vaccine over 28 days delivered in the muscle or the skin (Figure 5.7a and c, 
p=0.86 and 0.95 for types 1 and 3, respectively). However, antibody titers in both IM and 
ID extended delivery groups were significantly higher than their bolus counterparts (Figure 
5.7a and c, p<0.001). This indicates that extended delivery is beneficial after IM as well as 
ID vaccination. Furthermore, antibody titers remained high up to six months after 
vaccination. Extended delivery into the skin was the only group to maintain 100% 
seropositivity at six months after initial vaccination (Figure 5.8). This suggests that 
extended delivery vaccination induces long-lasting improvements in immune response.  
 
Figure 5.7. Route of delivery- Titers at day 56 and 168. 
IPV neutralizing antibody titers for type 1 are shown in panel a, for type 2 are shown 
in panel b, and for type 3 are shown in panel c (ns- p>0.05; * p<0.05; ** p<0.01; *** 
p<0.001; **** p<0.0001). Day 56 is represented by the left bar, and day 168 is the 
right bar. Extended delivery in the skin or muscle induces potent immune response 
compared to bolus vaccination with no difference between the two locations. Total 
dose was 25% of a human dose (10 DU of IPV type 1, 2DU of IPV type 2, and 8 DU of 
IPV type 3). 
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Figure 5.8. Route of delivery- Titers over time and seropositivity. 
IPV type one neutralizing antibodies are represented in panels a and d; IPV type two 
in b and e; and IPV type three in c and f. The top row of panels shows the titers over 
time, with the arrow representing the boost on day 28 and the dotted line representing 
the baseline of the assay. The bottom row shows seropositivity at day 56 and day 168 
(6 months). 
5.3.4 Applicability to multiple vaccines 
We next wanted to determine if the extended delivery profile we studied using IPV 
would broadly apply to other vaccines. To this end, we replicated this experiment using 
tetanus toxoid vaccine, live attenuated measles vaccine, and subunit influenza vaccine. 
For the tetanus toxoid study, tetanus toxoid vaccine was administered ID to Balb/c 
mice either as a bolus (Bolus-P-ID) or via repeated ID injections over 28 days (ED-28day-
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ID). Anti-tetanus toxoid IgG titers at day 28 were induced using extended delivery of the 
vaccine compared to bolus delivery (Figure 5.9b, p<0.0001). This shows that extended 
delivery can improve immune responses to a toxoid vaccine.  
 
Figure 5.9. Applicability to multiple diseases. 
(a) IgG titers following extended delivery of tetanus toxoid into the skin are 
significantly higher than titers following a bolus delivery (**** p<0.0001). (b) Day 42 
IgG titers following extended delivery of tetanus toxoid into the skin are significantly 
higher than titers following a bolus delivery (**** p<0.0001). (c) Measles virus 
neutralizing antibody titers over time were determined using a plaque reduction 
neutralization assay. (d) Titers at day 28 were not significantly different between the 
two groups (ns p>0.05). Total dose for tetanus vaccine was 100% of a human dose 
(5Lf); total dose for measles vaccine was 20% of a human dose (200TCID50). 
Live-attenuated measles vaccine was administered intradermally to cotton rats. The 
bolus and extended delivery over 28 days were indistinguishable from each other (Figure 
5.9d, p=0.700), indicating that extended delivery did not improve immunogenicity of this 
live-attenuated vaccine. This may be because the live-attenuated measles vaccine already 
effectively mimics an infection with extended presentation of antigen.  
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In the influenza vaccine study, subunit vaccine was delivered by intradermal 
injection. Bolus groups were boosted on day 77; hemagglutinin inhibition (HAI) titers were 
measured at days 28 and 107. Before the boost, HAI titers for the extended delivery group 
(ED-28 day-ID) was significantly higher than the bolus prime + boost group (Bolus-P+B-
ID) (Figure 5.10, p=0.006). After the bolus group received the boost, the higher HAI titers 
were comparable to the extended delivery group (p=0.695).  These data indicate that 
extended delivery can improve responses to a sub-unit vaccine and reduce the number of 
doses necessary to achieve an immune response above levels that are protective in humans 
[196].  
 
Figure 5.10. Subunit influenza vaccine- Titers at day 56 and 107. 
HAI titers pre-boost on day 56 and post-boost on day 107 show higher titers for a 
single dose of the extended delivery compared to a single bolus dose (*p<0.05, 
***p<0.001). Following the boost, HAI titers were equivalent across all groups. The 
solid line at 5 indicates the detection limit, and the line at 40 represents titer which is 
considered seropositive. Total dose was 6.7% of a human dose (1ug). 
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Figure 5.11. Subunit influenza vaccine- Titers over time and seropositivity. 
(a) HAI titers over time, with the arrow representing the boost on day 77 and the 
dotted line representing the baseline of the assay. (b) Seropositivity (titers>40) for 
each group is shown for each time point. 
5.3.5 Delivery using microneedle patches 
MN patches have been shown to effectively deliver vaccines into skin and to 
increase immune responses compared to injections. Here, we administered MN patches 
loaded with subunit influenza vaccine to Balb/c mice either as a bolus or extended delivery 
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over 28 days. Bolus groups vaccinated via MN patch or ID injection were boosted on Day 
77. Before the boost, extended delivery using MN patches induced higher HAI titers 
compared to bolus vaccination by intradermal injection or MN patch (Figure 5.10, p=0.025 
and 0.037, respectively). Furthermore, mice vaccinated via MN patch extended delivery 
had higher HAI titers at day 28 compared to repeated ID injections (Figure 5.11). After the 
boost, the HAI titers for mice boosted with a second bolus dose are not significantly 
different compared to the single dose extended delivery groups (p>0.6). This shows that 
extended delivery of a single dose of influenza vaccine given by MN patch can produce 
immunity similar to two bolus doses of vaccine. 
5.3.6 Extended delivery induces a balanced immune response 
Motivated by increases in antibody titers, we performed a series of experiments to 
further understand the effects of long-term antigen presentation on the immune response. 
In this study, we compared extended delivery using MN patches (ED-28day-MN) to a 
bolus MN patch (Bolus-P-MN), bolus ID injection (Bolus-P-ID), and a prime + boost group 
(Bolus-P+B-ID). Additional controls were added: one group received a bolus vaccination 
via MN patch on day 0 followed by placebo patches for the remainder of the 28 days 
(Bolus-P-MN + ED-Placebo-MN); another group just received a placebo patch on day 0 
(Bolus-Placebo-MN). The former group is meant to look at the effect of repeated injury 
after skin vaccination (which is an inherent part of the extended delivery method used in 
this study). Serum antibody titers were measured weekly, while the cellular responses were 
measured at day 35, which was one week after the final vaccination for the ED group and 
one week after the boost.  
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First, we analyzed the IgG, IgG1, and IgG2a of mice vaccinated with subunit 
influenza vaccine. In all cases titers increased with time. Total influenza IgG titers were 
highest in mice that received extended delivery with MN patches compared to all other 
groups, including the bolus prime + boost group (Figure 5.12a, p<0.05). These mice also 
had the highest IgG1 and IgG2a titers (Figure 5.12c and d, p<0.0001). The ratio of 
IgG1/IgG2a was similar among all of the MN patch groups, and were about 10-fold higher 
than the ID vaccination groups (Figure 5.12b).  
All animals were euthanized on day 35, and bone marrow, lymph nodes, and spleen 
were collected and analyzed for cellular responses. Strong germinal center (GC) and T 
follicular helper cell (Tfh) responses are desirable for high affinity antibody and long-lived 
antibody secreting plasma cell (ASC) responses. Using flow cytometry, we examined the 
GC B cells (GC B) and Tfh in the lymph nodes at day 35. Extended delivery with MN 
patches generated the strongest responses in these cell populations, which was significantly 




Figure 5.12. Humoral and cellular response. 
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Serum IgG (a), IgG1 (c), and IgG2a (d) are shown at day 35. Extended delivery with 
MN patches induced higher antibody titers compared to all other groups. The ratio 
of IgG1 to IgG2a (b) were approximately equivalent for all MN groups. Lymph nodes 
had higher percentage of germinal center B cells (e) and T follicular helper cells (f) 
compared to mice vaccinated by intradermal injection, but not higher than those 
receiving a MN prime dose followed by placebo patches. Antibody secreting cells for 
IgG1 (g) and IgG2a (h) were present in higher numbers in the bone marrow in mice 
vaccinated with extended delivery (MN-ED) than bolus MN patch vaccination. (i) 
Splenocytes that were restimulated with antigen secreted higher concentrations of 
IFN ɣ after extended delivery vaccination. Plasmablasts in the lymph nodes were 
comparable at day 35 (* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). Total dose 
was 6.7% of a human dose (1ug). 
ASCs go to the bone marrow following a vaccination or infection and are associated 
with long-term memory response and antibody production [197]. Both IgG1 and IgG2a 
ASCs in the bone marrow were significantly more prevalent after extended delivery by 
MN patch than bolus vaccination by MN patch (Figure 5.12g and h, p=0.024 and 0.010, 
respectively). While ASCs, GC B, and Tfh responses were stronger after extended delivery 
by MN patch compared to the bolus MN patch followed by repeated placebo patches, this 
difference was not statistically different in this small data set (Figure 5.12e-h, p>0.999). 
This suggests that repeated injury from MN patch application may play a role in the 
immune response seen after extended delivery vaccination. Plasmablast levels in the lymph 
nodes on day 35 were not significantly different across all groups after vaccination (Figure 
5.13). This lack of differences in responses may be because measurement at day 35 was 
too late in the immune response process as suggested by prior literature [109].   
Finally, splenocytes were re-stimulated with antigen, and the supernatant was 
analyzed for IFN-gamma level by ELISA.  Again, extended delivery by MN patch showed 
the strongest IFN ɣ response, indicating a strong Th1 cellular response. IFN ɣ levels were 
elevated following extended delivery with MN patches compared to all other groups, 
although this difference was not significant in most cases (Figure 5.12i). Taken together, 
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extended delivery vaccination with MN patches amplified the humoral immune response 
through increased antigen-specific antibody, GC B cell, Tfh, ASC and Th1 responses. 
 
Figure 5.13. Plasmablast response. 
Plasmablasts in the lymph nodes were comparable at day 35. 
5.4 Discussion  
While vaccines provide one of the most powerful and cost-effective tools in public 
health, insufficient vaccination coverage limits the impact of vaccines. Studies show that 
1.5 million lives could be saved by improved vaccination coverage, both in terms of first-
dose vaccination and completing vaccination series [172]. One way to improve vaccination 
coverage is to reduce the number of vaccine doses so that, for example, a single vaccination 
can provide full protection without the need for booster doses. Vaccines could also improve 
impact on public health by increasing vaccine immunogenicity without the added cost of 
increasing vaccine dose or the use of adjuvants. For those vaccine that already generate 
robust immune response in current formulations, increased immunogenicity could enable 
cost savings by lowering the dose administered. Finally, the reach of vaccines could be 
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improved by simplifying the logistics of vaccination, such as less reliance on cold-chain 
refrigeration, avoidance of biohazardous sharps waste and reduced need for highly trained 
healthcare personnel to administer vaccines. 
With these goals in mind, this study sought identify ways to increase vaccine 
immunogenicity without increasing vaccine dose, reduce the number of doses needed to 
achieve protective immunity and assess the possible use of simplified vaccination methods. 
We did so by studying the effect of kinetic profile of vaccine release into the skin on 
immune response during extended delivery, assessing the potential to increase 
immunogenicity and/or reduce the number of doses using four licensed vaccines of 
significance to public health, and to further understand the immune response to extended 
vaccine delivery. 
5.4.1 Vaccine delivery profile  
The concept of extended release of vaccines has been utilized previously to have 
an adjuvant effect; however, in most cases, the systems were developed to prolong 
exposure and follow similar release profiles with an initial burst followed by low levels of 
release [39, 89, 93]. Few have studied how differences in antigen profiles can affect the 
immune response. We began by using inactivated polio vaccine (IPV) to look at the optimal 
profile and length of release. From Figure 5.2, Constant and Exponentially Increasing 
profiles induced higher neutralizing antibody titers compared to single bolus injection.  
These results indicate that vaccination profiles that roughly follow natural infection 
kinetics are preferred over bolus or profiles with an initial burst. Other studies using model 
protein antigens found that using natural infection kinetics can improve the immune 
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responses over bolus injections [92, 109, 113]. Some studies have suggested that these 
kinetic profiles induce better T-cell stimulation and prolongs T-cell memory for a particular 
antigen, indicating activation of both cellular and humoral arms of the immune system [89].  
We also identified that longer stimulations of the immune response can elicit better 
responses, with release over one month performing better than release over one or two 
weeks. It is possible that even longer exposures could induce stronger reactions, although 
an extremely low vaccine release rate over a longer time could be insufficient to generate 
an immune response or could even induce tolerance to the antigen [198, 199].  
Today, most vaccines are administered IM; previous work has demonstrated that 
controlled-release systems such as microparticles given via IM injection produce 
comparable results to subcutaneous and intranasal delivery [200] [201]. Vaccine delivery 
into the skin is becoming a more promising option due to the potential for enhanced 
immune response for some vaccines in the skin and the ease of delivery into the skin with 
novel devices [158, 202, 203]; however, no studies have directly compared IM and ID 
vaccination with extended delivery. Here, we showed that administering daily doses into 
the skin or into the muscle induced comparable immune responses, both of which were 
superior to bolus doses. This result motivates the development of a controlled release MN 
patch that could ease the logistical challenges of vaccinations by reducing the total number 
of doses and by simplifying the vaccination administration, as discussed below.  
Compared to inactivated vaccines, live-attenuated vaccines are known to induce 
potent immune responses and require fewer boosters to provide long-lasting protection. As 
the vaccine infects and replicates in its host, the host’s exposure to the vaccine is prolonged, 
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innately providing extended exposure to the antigen for roughly 14 days [204]. Therefore, 
we predicted that prolonging antigen delivery through repeated injections will not be 
advantageous for a live-attenuated vaccine. Consistent with this hypothesis, the live-
attenuated measles vaccine did not induce a more potent immune response with extended 
delivery when compared to bolus vaccination, whereas the three inactivated or protein-
based vaccines did.  
5.4.2 Improved immunogenicity of licensed vaccines 
In this study, extended delivery improved immunogenicity of three licensed 
vaccines: IPV, tetanus toxoid and subunit influenza vaccines. This suggests that our finding 
may be applicable to a broad range of non-replicating vaccines of significance to public 
health. 
5.4.2.1 Inactivated polio vaccine 
As the polio eradication initiative approaches its conclusion, IPV is being 
increasingly administered across the world. Vaccine shortages as well as the relatively high 
cost of IPV has led to a WHO recommendation for use of a one-fifth dose of IPV 
administered ID as a two-dose regimen that than the conventional three full-strength doses 
administered IM [205]. The improved immunogenicity of IPV when administered ID by 
extended delivery could enable further dose reduction and/or reduce the number of vaccine 
doses, possibly reducing the two-dose ID regimen to a single dose.  
5.4.2.2 Tetanus toxoid 
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Tetanus toxoid is currently given as a multi-dose regimen with 5 – 6 doses in 
childhood followed, in some cases, by repeated boosters in adulthood and during 
pregnancy [122]. Extended delivery of tetanus toxoid could reduce the number of doses 
and/or frequency of boosters, thereby simplifying the vaccination schedule that includes 
vaccination older children and adults outside the primary childhood vaccination schedule.  
5.4.2.3 Influenza vaccine  
Influenza vaccine is given as a two-dose regimen upon first vaccination of children, 
followed by annual re-vaccination for life where high-dose vaccination is recommended in 
the elderly [206]. Extended-delivery vaccination could eliminate the need for two doses 
upon first vaccination, reduce the doses needed during annual vaccination campaigns 
including the high-dose vaccine administered to the elderly.   
5.4.3 Microneedle patches allow for extended delivery 
In this study, we were motivated to study extended delivery in the skin because of 
the increased immunogenicity of skin vaccination[27, 41, 43, 45, 167], as well as the 
opportunity to use MN patches that not only target skin, but can also simplify vaccination 
logistics [26, 158]. While administering intradermal injections via the Mantoux method 
requires an experienced provider, MN patches are a novel method to easily vaccinate large 
numbers of people. Vaccination via MN patches has been previously shown to induce a 
potent immune response [5, 9, 13, 28, 45, 161]. Here for the first time, we demonstrated 
that daily vaccination with dissolving MN patches produced even higher HAI titers 
compared to daily intradermal injections. We hypothesize that this is due to the differences 
in delivered volume and viscosities. Injections are a large volume of saline forced into the 
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skin at a high pressure. The saline and vaccine quickly disperse throughout the skin, and 
the vaccine can be cleared by immune cells. Conversely, an inserted microneedle patch 
contains sugars and polymers which can form a transient gel in the skin [115, 207]. The 
polymers used here have been shown to dissolve and release their cargo on the order of 
hours. This work motivates future development of a single microneedle patch which can 
slowly dispense vaccine over the course of one month.    
5.4.4 Immune response to extended delivery  
In order to characterize the immune response, we analyzed the IgG, IgG1, and IgG2a 
isotypes in the mouse serum after influenza vaccination. We note that vaccine 
administered over the course of one month induced higher titers across all isotypes [107, 
208-210]. Studies using controlled release of vaccines have found increases in both IgG1 
and IgG2a titers; however, there is no clear consensus on whether the response is skewed 
towards a Th1 [211, 212] or Th2 response [209, 213, 214].  Strong GC reaction and Tfh cell 
response are known to  generate high affinity antibody, isotype switching and lasting 
immune memory [215]. Repeated administration of MN patches had increased levels of 
GC B and Tfh cells in lymph nodes and antibody secreting plasma cells in bone marrow, 
suggesting strong humoral and memory responses. Also, repeated MN patches had high 
Th1 response. High GC B and Tfh cell numbers along with high serum antibody titers have 
been seen in previous MN patch work and have shown to be correlated with rapid virus 
clearance and survival following lethal challenge [45]. Daily injected vaccination and slow 
release formulations with MN patches have demonstrated increased CD8+ T-cells 
 99 
responses [92, 115, 117]. Taken together, repeated application of MN patches elicits 
superior humoral and cellular immunity compared to bolus vaccinations.  
We additionally noted increased responses in the bolus MN patch vaccination 
followed by repeated placebo MN patches. While this response was not as great as 
repeated vaccination, it was superior to bolus MN patch vaccination. This suggests that 
repeated injury to the site of vaccination is enhancing the immune response and that the 
increase in the extended delivery group is not solely due to antigen exposure. Repeated 
application of MN patches did not induce increased infection or inflammation markers 
[118]; however, prolonged presence of antigen following MN patch delivery increased 
local inflammation [117]. Additionally, there is evidence that colocalization of the antigen 
with cell death can enhance the humoral response and CD8+ T-cell induction [216, 217]. 
More work will need to be done to determine the role of repeated injury at the site of 
vaccination on the immune response.  
In this work, we demonstrated the impact of extended delivery of vaccines by 
utilizing daily intradermal injections. These injections allowed us to replicate different 
release profiles without the added complications of utilizing different controlled release 
systems. While repeated injections are not a practical method to administer vaccines, this 
work motivates the development of controlled release systems for a single vaccination. 
Injectable controlled release systems such as poly(lactic-co-glycolic acid) (PLGA) 
microparticles and thermosensitve hydrogels have been shown to be able to release 
proteins over the course of weeks to months [218, 219]. However, an even stronger 
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approach would be to combine the benefits of a controlled release system with those of 
microneedle patches [33]. Using controlled release formulations in microneedle patches 
has been previously accomplished using PLGA, poly(acrylic acid), and silk, among others, 
although these patches elicit significant burst releases that we have shown to be a 
detriment to inducing a large immune response [115-117]. Novel MN patch formulations 
are necessary to achieve single vaccination without this burst.  
5.5 Conclusion  
In conclusion, this study showed that extended delivery of vaccines to the skin 
enabled a single dose of vaccine delivered over the course of one month to provide similar 
immune responses to vaccination using two bolus doses in a prime plus boost protocol. 
This method improved the immune response to three different killed vaccines, but not to a 
live vaccine. Furthermore, we demonstrated that the humoral response lasted at least six 
months and that delivering the doses via dissolving MN patches increased both the humoral 
and cellular responses to the vaccines. Antigen extended delivery has the potential for dose 
sparing or eliminating the number of boosts required to reach protective levels.  
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CHAPTER 6. DISCUSSION 
Vaccinations have been one of the most important life-saving health care 
technologies in the last century. Immunizations prevent between two and three million 
deaths each year [3]; however, an addition 1.5 million lives could be saved each year with 
increased vaccination coverage. Apart from oral polio, rotavirus, and cholera vaccines and 
intradermal Bacille Calmette-Guérin vaccine, all currently recommended vaccines by the 
WHO require administration with a needle and syringe to deliver the vaccine into the 
muscle or subcutaneous space. This technology creates numerous logistical problems that 
can be costly during vaccination campaigns. Briefly, the needle and syringes must be 
properly disposed after vaccination; trained healthcare providers are required to 
reconstitute and administer the vaccines; the cold chain, an expensive series of 
refrigerators, is required to maintain viral activity during shipping and storage; and multiple 
doses of vaccines may be necessary to invoke a long-lasting immunity to an antigen.  
In this work, we developed microneedle (MN) patches to replace the needle and 
syringe when administering vaccines. Dissolving MN patches are single dose, single use 
patches that painlessly deliver the vaccines into the skin. Once dissolved, the needles can 
no longer be used, and the remaining backing can be discarded as regular waste. Patches 
can be administered by minimally trained personnel or even self-administered. These 
patches can be stored outside the cold chain for extended periods of time. With some 
vaccines, the intradermal vaccination improves the immune response allowing for dose 
sparing. However, these patches must be formulated and tested for each vaccine antigen 
delivered.  
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This work sought to fill two gaps of knowledge in the MN space. The first was the 
development of a MN patch to deliver measles and rubella (MR) vaccines. These live-
attenuated vaccines are among the most unstable vaccines that are currently licensed [25]. 
Additionally, two doses of the vaccine are necessary to achieve high (>95%) population 
immunity, and the first dose cannot be administered until 12 months of life [47]. In the 
second part of this work, we utilized extended presentation of an antigen as a method to 
improve the immune response to vaccination with an injection or with a MN patch. Many 
vaccines such as inactivated polio vaccine or tetanus vaccine require two or more doses to 
be effective; while other vaccines such as seasonal influenza vaccine suffer from low 
efficacy, limiting the protectiveness of vaccination.  
In the first chapter, we developed thermostable MR MN patches. Buffers were 
crucial to maintain rubella vaccine activity during drying, but were not essential for 
measles vaccine. Various sugars, amino acids, and proteins can be used to stabilize MR. A 
combination of sucrose and threonine were used to demonstrate that MR MN patches could 
withstand long term storage at elevated temperatures. The thermostability allows the 
patches to be stored outside the cold chain. The necessity to maintain 2-8˚C during 
shipment and storage accounts for a significant portion of the cost of single vaccination 
and leads to substantial vaccine wastage. Utilizing the formulations developed here, 
patches can be shipped without refrigeration, reducing the cost of vaccinations. This will 
also allow for vaccination in more remote areas that currently have trouble accessing 
vaccinations.  
Juvenile and infant rhesus macaques were vaccinated using MR MN patches to 
assess the safety and immunogenicity of the patches as compared to a subcutaneous 
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vaccination. After MN patch administration, slight redness at the site was present for about 
an hour, but no adverse events were noted. The humoral response was studied after 
vaccination and after measles viral challenge; all data demonstrated that the MN patches 
induced potent immune responses to both vaccines that was equivalent to the subcutaneous 
vaccination. Unfortunately, MN patches were unable to overcome the presence of maternal 
antibodies and induced an inferior response compared to naïve vaccinations. Overall, MR 
MN patches were safe and immunogenic in a rhesus macaque model. This was the first 
time that infant rhesus macaques had been vaccinated with MN patches. Young immune 
systems are still developing and have weaker responses to vaccination. However, this work 
demonstrated the formation of a robust, protective response that was present at least six 
months after vaccination. This indicates that MN patches could be used in high-risk 
populations such as young, old, and immune suppressed. Taken together, these data support 
that vaccination utilizing a MN patch to deliver MR vaccines and that these patches could 
be beneficial in eradication efforts.  
In the second set of experiments, we studied the immune response to extended 
delivery of a vaccine antigen. We were inspired by different types of vaccines. Live-
attenuated vaccines, such as MR, must replicate in the patient and provide life-long 
protection against the pathogen. Inactivated or subunit vaccines, on the other hand, are 
safer but do not always induce strong responses. Inactivated polio vaccine (IPV) must be 
administered at least 3 times for 95% of the population to respond [220]. Through this 
work, we sought to combine the safety of inactivated vaccines with the immune response 
of a replicating vaccine. We hypothesized that kinetics that mimicked natural infections 
would induce a more potent immune response. Using daily intradermal injections or MN 
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patches, a zeroth order, constant release profile over 28 days induced the most potent 
immune response. The improved immune response is seen over a range of inactivated 
vaccine types: IPV, tetanus toxoid, and subunit influenza vaccine; however, extended 
delivery of live-attenuated measles vaccine did not enhance the immune response 
compared to a bolus injection. Furthermore, daily MN patches delivering flu antigen 
induced strong neutralizing antibodies and cellular response. Future work could address 
formulation of MN patches for extended vaccine delivery after application of a single 
patch.  
By implementing antigen extended delivery in vaccination strategies, the improved 
immune response to a single dose could increase the number of people protected against 
various pathogens. This technique can lower the required number of doses for 
seroconversion. For vaccination campaigns and elimination/eradication efforts, reaching 
populations in rural or politically unstable areas is particularly difficult. Limiting the 
number of times vaccinators must travel to these areas can save money and allow for better 
allocation of resources to achieve elimination/eradication goals. Extended delivery could 
also allow for dose sparing, or using a lower dose to achieve an equivalent immune 
response. Dose sparing can save antigen during vaccine shortages, such as manufacturing 
malfunction or pandemic flu outbreak, while maximizing the number of people vaccinated. 
Thus, extended delivery can improve vaccination coverage and reduce vaccine-preventable 
deaths worldwide.  
In this work, dissolving MN patches were developed and tested for thermostability 
and strong immunogenicity. There remains a need to develop the manufacturing 
technology to increase production for dissolving MN patches. Other technologies are under 
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development for intradermal delivery of vaccines. Coated MN patches, consisting of a 
vaccine solution dried onto metal MNs, are comparable to dissolving MN patches in many 
aspects; however, the needles remain sharp after insertion, which could lead to disease 
spread through needle re-use and improper disposal [221]. Particle and jet injectors utilize 
a high-pressured stream of gas or liquid to push vaccines through the upper layers of the 
skin. These benefit vaccination campaigns by removing any sharps waste; jet injectors can 
utilize current formulations while particle injectors would require reformulation. External 
pressure-generating devices and significant nurse training are required to administer these 
vaccines. Jet injectors have been used in clinical trials to mixed success [185, 222]. Other 
methods for delivering vaccines, such as electroporation, ultrasound, and thermal/chemical 
abrasion, are underdevelopment but may be cost prohibitive for developing countries [185].  
Vaccinations hold great potential in reducing the global disease burden. However, 
current technologies hamper delivering the life-saving vaccines. Novel vaccine delivery 
technologies will be a key part in reaching high vaccination coverage and eradication of 
polio, measles, rubella, and other viruses. Dissolving MN patches can reduce the cost and 
ease logistics for vaccinations, especially in developing countries. These patches eliminate 
biohazardous sharps waste, are well tolerated by patients, and can be administered by 
minimally trained personnel. These patches can be removed from the cold chain and induce 
potent, long-lasting responses.  Thus, MN patches have great potential to safely and 
effectively deliver vaccines and increase vaccination coverage.   
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CHAPTER 7. FUTURE DIRECTIONS 
7.1 Add mumps vaccine to the measles-rubella microneedle patch 
In this project, thermostable, immunogenic measles-rubella (MR) microneedle 
(MN) patches were developed. Currently, these vaccines are co-administered with live-
attenuated mumps vaccine (measles-mumps-rubella (MMR)). The World Health 
Organization (WHO) has stated that mumps could be eliminated if two-dose vaccine 
coverage were increased; however, mumps has not received as many resources compared 
to MR based on global mortality and disease burden [223-225]. Routine mumps 
vaccination is recommended in countries with established MR vaccination coverage 
(>80%), and two doses are necessary for high levels of immunity in a community [225].  
Mumps vaccine has been delivered as part of an MMR formulation by jet injector 
[58, 60, 226] and aerosol [66]. Clinical trials have demonstrated positive immune response 
data for these alternative delivery methods, suggesting that delivery of mumps vaccine with 
a MN patch would induce a potent immune response. Adding novel vaccines to a MN patch 
requires reformulation and evaluation of said patch to ensure that activity of all vaccine 
components is retained. Compared to measles vaccine, mumps vaccine has been shown to 
be more resilient to centrifugation for filtration, low pH, and elevated temperature in liquid 
state [77]. However, little data exists of the stability of mumps vaccine during drying and 
storage. Because the current licensed product is a lyophilized vial, we can predict that the 
vaccine can withstand MN patch manufacturing. More studies are necessary to predict the 
potential for long-term storage in the MN patch.  
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7.2 Improve the stability of the measles-rubella vaccine microneedle patch  
 Maintaining vaccine activity during storage is critical to the success of MN patches 
in the developing world. The current lyophilized vials are have a shelf life of 2 years at 2-
8˚C or one month at 37˚C, in which vaccine activity decreases by 1 log [55]. In our 
experiments, MR MN patches were stable at 40˚C for up to one month with no loss and up 
to two months with 1 log loss of activity. Improving the stability at elevated temperatures 
would allow the patches to travel further, thereby improving access to more rural areas 
[49]. Screening studies are time and resource intensive; carefully selecting the parameters 
to test is crucial to ensuring rapid success. We only worked with combinations that were 
equal mass ratios, but other work in the group has demonstrated that the ratio of the 
excipients can play a critical role in the stability of the vaccine (inactivated polio vaccine, 
unpublished). Additionally, in other studies, divalent cations were proven helpful in 
stabilization during spray drying measles vaccine [74]. Including these cations with 
sugar/amino acid combinations may improve stability during manufacturing and storage. 
Any novel formulations should be tested for their stabilizing nature during short and long-
term storage. Additionally, MN patches could be examined for their mechanical strength 
after storage. Previous work has demonstrated that MNs remained sharp after storage for 
one year with desiccant [9]; however, this may change based on patch formulation. Finally, 
only in vitro cell infectivity assays have been used to assess stability. An in vivo study in 
cotton rats or rhesus macaques could be used to further demonstrate that patches retained 
viral activity and immunogenicity after extended storage.  
7.3 Prepare the measles-rubella microneedle patch for clinical trials 
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At the conclusion of this project, efforts are underway to scale up the MR MN 
patches for a phase 1 clinical trial. To date, influenza vaccine is the only vaccine to be 
administered via a dissolving MN patch in a clinical trial. These studies demonstrated that 
the MN patch was safe and well-tolerated by the patients and were able to induce a robust 
immune response [6, 16].  
To meet the demand for a clinical trial and eventual market release, the 
manufacturing process used in this work will need to be adjusted. The methods used in this 
work are labor intensive, low throughput, and can lead to vaccine wastage and variable 
dose loading. Novel techniques could be used to allow more precise MN manufacturing. 
Filling PDMS molds using a roller method [227] could reduce the volume required for 
patch manufacturing, as well as ensure the vaccine is near the tips for higher delivery 
efficiencies. Dissolving MN patches have been 3-D printed, offering flexibility in MN 
shape, dose loading, and dose distribution within the MN [228]. However, no one has yet 
loaded vaccines into these patches; it is unknown if the vaccine would be able to withstand 
this manufacturing process. In addition, quality assurance and control mechanisms must be 
put in place to ensure proper sterilization of the MN patches and consistent dosing [15, 
229].  
7.4 Fabricate controlled release patch for single administration 
In this work, we demonstrated that daily microneedle patches improve the immune 
response compared to a single vaccination. These patches could be provided in a pre-
packaged set, and the patient could apply the patches daily [16]. However, this strategy is 
not practical, especially in a low resource setting. A novel controlled release MN patch 
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requiring only a single administration could increase patient compliance. The MN patch 
would need to quickly dissolve from the backing, releasing the MNs into the skin. Then, 
the MNs could slowly release vaccine over the course of one month.  
Numerous MN systems have been designed to slowly release proteins at various 
rates. These systems can be divided into two categories: (1) the needles break off to act as 
a reservoir in the skin or (2) particles are loaded into the needles, surrounded by faster 
dissolving matrix. In the first scenario, full needles were cast of the drug and a polymer 
such as poly(lactic-co-glycolic acid) (PLGA), and a metal or rapidly dissolving polymeric 
support structure was used to insert the needles fully into the skin [115, 116, 140]. Other 
similar systems have been developed to deliver entire needles into the skin [230]. Another 
method is to encapsulate micro- or nanoparticles into the MN patches. Various water-
soluble polymers and sugars can entrap the particles in the MN array and provide the 
mechanical strength necessary to pierce the skin. Once the polymers and sugars dissolve, 
the particles remain in the skin and can release their cargo at a determined rate [7, 115]. 
These particles could be coated onto metal structures using increased viscosity [231] or 
layer-by-layer assembly [232].  
One unknown of this work is how the reservoir will remain in the skin during the 
release. Skin cells are constantly being replaced in the basal layer of the epidermis and are 
then pushed into the upper layers as the older cells die and are removed. This process can 
take approximately 20-40 days [233, 234]. To date, particles have delivered antigen in the 
skin continuously for up to two weeks [115, 235].  
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CHAPTER 8. CONCLUSION  
MN patches are an innovative technology to administer vaccines without needles 
and syringes. With its numerous advantages, these patches can reduce costs and ease 
logistics for vaccinations. When used in eradication efforts, the patches developed here can 
reduce the necessary resources for vaccination campaigns, freeing those resources for more 
campaigns or other activities such as surveillance and outbreak response.  In this work, we 
developed the first measles-rubella (MR) vaccine MN patch. This patch was thermostable, 
raised no significant safety concerns, and induced potent immune responses in infant and 
juvenile rhesus macaques.  In the second part of this thesis, daily exposure to small doses 
of a vaccine induced higher neutralizing antibodies compared to a bolus vaccination. This 
work enhances the MN community’s understanding of vaccine stability and intradermal 
vaccination and can serve as a powerful tool to expand global access to vaccinations.  
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APPENDIX A. MEASLES- RUBELLA STABILITY TABLES 
Table 1. Single excipients stored from one week at elevated temperature. 
Vaccines were dried with at room temperature overnight and stored with desiccant 
for one week at 40°C (Figure 3.3). The activity after drying is reported as the percent 
activity compared to the liquid control. The activity loss during storage is reported as 
the percent activity at day 7 compared to the activity at day 0. The excipients that 
were used in the next phase are highlighted.  
 
 
Excipient Measles Rubella 
 % at Day 0 to 
Liquid Control 
% at Day 7 
to Day 0 
% at Day 0 to 
Liquid Control 
% at Day 7 
to Day 0 
Na Lactate 19.1% 0.0% 28.0% 1.5% 
Histidine 1.0% 35.5% 32.9% 9.0% 
Dextrose 23.7% 0.0% 32.9% 0.0% 
Asparigine 3.8% 0.0% 13.9% 7.6% 
Threonine 1.6% 0.0% 55.9% 1.5% 
Glycine 0.5% 0.0% 35.2% 1.2% 
Adonitol 26.3% 0.0% 25.7% 0.0% 
Serine 11.7% 0.0% 20.2% 2.1% 
Na Citrate 0.8% 0.0% 4.6% 0.0% 
Na Thiosulfate 27.9% 0.0% 4.8% 0.0% 
Sucrose 8.4% 6.9% 29.4% 22.7% 
K Gluconate 4.0% 0.0% 116.8% 4.7% 
Sorbitol 9.9% 0.0% 144.3% 4.2% 
Na Gluconate 15.2% 0.0% 154.1% 3.6% 
Maltose 0.7% 0.0% 87.6% 0.7% 
Glucose 3.2% 0.0% 53.7% 0.0% 
Mannitol 0.3% 0.0% 50.6% 4.2% 
K Citrate 0.0% 0.0% 55.1% 0.0% 
Myo-inositol 1.2% 0.0% 35.7% 5.0% 
MADPG 0.3% 0.0% 12.0% 0.0% 
Trehalose 3.7% 20.8% 110.3% 8.5% 
Na Phosphate 0.5% 0.0% 0.0% 0.0% 
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Table 2. Measles vaccine combination screen. 
Measles vaccine was dried in dual excipient combinations overnight at room 
temperature and stored for one week at 40°C. The activity remaining at day 0 and 7 
are shown in Figure 3.4(top).  
 
Excipient 1 Excipient 2 Code 








% Day 7 







Histidine Sucrose H-S 26 % 0.071 Y 29% 0.126 Y 
Histidine Trehalose H-T 12% 0.036 N 27% 0.374 Y 
Histidine Asparagine H-A 3% 0.023 N 8% 0.379 Y 
Histidine Maltose H-M 13% 0.039 N 0% 0.146 Y 
Histidine Sorbitol H-So 15% 0.041 N 4% 0.076 Y 
Histidine K Gluconate K-KG 13% 0.039 N 0% 0.146 Y 
Histidine Dextrose H-D 7% 0.028 N 0% 0.013 N 
Histidine Na Gluconate H-NaG 26% 0.071 Y 6% 0.249 Y 
Sucrose Trehalose S-T 7% 0.028 N 11% 0.019 N 
Sucrose Asparagine S-A 33% 0.098 Y 44% 0.045 N 
Sucrose Maltose S-M 7% 0.029 N 0% 0.034 N 
Sucrose Sorbitol S-So 9% 0.032 N 0% 0.028 N 
Sucrose K Gluconate S-KG 13% 0.039 N 3% 0.153 Y 
Sucrose Dextrose S-D 8% 0.03 N 0% 0.12 Y 
Sucrose Na Gluconate S-NaG 13% 0.039 N 9% 0.171 Y 
Trehalose Asparagine T-A 117% 0.7 Y 12% 0.282 Y 
Trehalose Maltose T-M 7% 0.028 N 0% 0.013 N 
Trehalose Sorbitol T-So 11% 0.034 N 2% 0 N 
Trehalose K Gluconate T-KG 8% 0.03 N 0% 0.006 N 
Trehalose Dextrose T-D 4% 0.025 N 0% 0.194 Y 
Trehalose Na Gluconate T-NaG 1% 0.022 N 0% 0.028 N 
Asparagine Maltose A-M 4% 0.025 N 0% 0.194 Y 
Asparagine Sorbitol A-So 4% 0.025 N 12% 0.037 N 
Asparagine K Gluconate A-KG 3% 0.024 N 21% 0.337 Y 
Asparagine Dextrose A-D 3% 0.024 N 0% 0.327 Y 
Asparagine Na Gluconate A-NaG 5% 0.026 N 13% 0.091 Y 
Maltose Sorbitol M-So 4% 0.025 N 0% 0.346 Y 
Maltose K Gluconate M-KG 4% 0.025 N 0% 0.315 Y 
Maltose Dextrose M-D 1% 0.022 N 0% 0.146 Y 
Maltose Na Gluconate M-NaG 4% 0.025 N 0% 0.009 N 
Sorbitol K Gluconate So-KG 5% 0.026 N 0% 0.034 N 
Sorbitol Dextrose So-D 2% 0.022 N 0% 0.07 Y 
Sorbitol Na Gluconate So-NaG 4% 0.025 N 0% 0.315 Y 
K Gluconate Dextrose KG-D 5% 0.026 N 0% 0.07 Y 
K Gluconate Na Gluconate KG-NaG 22% 0.059 Y 0% 0.194 Y 
Dextrose Na Gluconate D-NaG 3% 0.024 N 0% 0.256 Y 
Sucrose Threonine S-Thr 5% 0.027 N 36% 0.3 Y 
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Table 3. Rubella vaccine combination screen. 
Rubella vaccine was dried in a combination of excipients and stored for one week at 
40°C. This data is represented graphically in Figure 3.4(bottom).  
 
 
Excipient 1 Excipient 2 Code 








% Day 7 
to Day 0 
t-test Day 




Histidine Sucrose H-S 8% 0.08 Y 61% 0.296 Y 
Histidine Trehalose H-T 33% 0.172 Y 59% 0.08 Y 
Histidine Asparagine H-A 20% 0.116 Y 147% 0.045 N 
Histidine Maltose H-M 19% 0.11 Y 135% 0.298 Y 
Histidine Sorbitol H-So 21% 0.118 Y 53% 0.011 N 
Histidine K Gluconate K-KG 34% 0.181 Y 24% 0.013 N 
Histidine Dextrose H-D 19% 0.113 Y 0% 0.024 N 
Histidine Na Gluconate H-NaG 27% 0.144 Y 30% 0.076 Y 
Sucrose Trehalose S-T 40% 0.215 Y 234% 0.331 Y 
Sucrose Asparagine S-A 10% 0.083 Y 157% 0.298 Y 
Sucrose Maltose S-M 38% 0.206 Y 101% 0.98 Y 
Sucrose Sorbitol S-So 37% 0.196 Y 192% 0.02 N 
Sucrose K Gluconate S-KG 24% 0.138 Y 226% 0.333 Y 
Sucrose Dextrose S-D 31% 0.163 Y 0% 0.056 Y 
Sucrose Na Gluconate S-NaG 13% 0.093 Y 261% 0.091 Y 
Trehalose Asparagine T-A 6% 0.074 Y 269% 0.136 Y 
Trehalose Maltose T-M 36% 0.189 Y 73% 0.192 Y 
Trehalose Sorbitol T-So 36% 0.192 Y 115% 0.264 Y 
Trehalose K Gluconate T-KG 57% 0.359 Y 5% 0 N 
Trehalose Dextrose T-D 39% 0.211 Y 0% 0.025 N 
Trehalose Na Gluconate T-NaG 44% 0.247 Y 13% 0.016 N 
Asparagine Maltose A-M 28% 0.149 Y 13% 0.027 N 
Asparagine Sorbitol A-So 44% 0.246 Y 10% 0.036 N 
Asparagine K Gluconate A-KG 74% 0.576 Y 9% 0.088 Y 
Asparagine Dextrose A-D 5% 0.072 Y 0% 0.067 Y 
Asparagine Na Gluconate A-NaG 7% 0.077 Y 0% 0.015 N 
Maltose Sorbitol M-So 63% 0.432 Y 0% 0.013 N 
Maltose K Gluconate M-KG 59% 0.383 Y 7% 0.001 N 
Maltose Dextrose M-D 52% 0.312 Y 0% 0.036 N 
Maltose Na Gluconate M-NaG 49% 0.285 Y 6% 0.001 N 
Sorbitol K Gluconate So-KG 44% 0.244 Y 6% 0.001 N 
Sorbitol Dextrose So-D 49% 0.284 Y 0% 0.045 N 
Sorbitol Na Gluconate So-NaG 49% 0.281 Y 19% 0.011 N 
K Gluconate Dextrose KG-D 33% 0.176 Y 0% 0.015 N 
K Gluconate Na Gluconate KG-NaG 61% 0.404 Y 13% 0.009 N 
Dextrose Na Gluconate D-NaG 29% 0.155 Y 0% 0.157 Y 
Sucrose Threonine S-Thr 51% 0.312 Y 43% 0.249 Y 
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APPENDIX B. INFANT MACAQUES VACCINATION DATA  
Table 4. Experimental design, measles neutralization titers, and measles virus titers 
in peripheral blood after challenge. 
  
Table 1: Experimental design, measles neutralization titers, and measles viral titers in 
























 45294 F 28 183 2 244 6.6 1.7 
 45338 M 18 199 56 234 4.3 0 
 45406 F 26 193 1407 228 0 0 
 45424 M 21 188 3647 223 0 0 
MN b 
 45437 M 45 219 6800 261 0 0 
 45478 F 32 206 3783 248 0 0 
 45506 M 24 198 302 240 0 0 
 45504 F 25 199 563 241 0 0 
SC + MiG b 
 45537 M 49 216 8 258 7.1 3.4 
 45546 F 42 209 87 251 7 2.5 
 45555 M 36 203 75 245 6.8 3.2 
 45559 F 34 201 2 243 6.7 3.3 
MN + MiG b 
 45450 F 42 216 15 258 5.7 2.5 
 45456 M 41 215 21 257 6.5 2.7 
 45507 M 24 198 43 240 5.7 2.7 
 45516 M 22 196 108 238 6.5 2.7 
Unvaccinated b 
 44323 F -- 110  376 7.9 2.7 
 44405 M -- 261  367 7.4 2.7 
 44452 F -- 255  361 6.7 3 
  44511 M -- 249   355 6.9 2.5 
 
(PC) post measles virus challenge.  
a. Copies of measles nucleoprotein RNA (MeVn) as log10 copies/106 PBMC or 
measles virus infectious titers as log10 TCID50/10
6 PBMC 
 
b. Rhesus macaques received subcutaneous (SC) or microneedle patch (MN) 
measles and rubella (MR) vaccination in the absence or presence of measles immune 
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